WO2015072125A1 - Anti-parvovirus composition - Google Patents
Anti-parvovirus composition Download PDFInfo
- Publication number
- WO2015072125A1 WO2015072125A1 PCT/JP2014/005626 JP2014005626W WO2015072125A1 WO 2015072125 A1 WO2015072125 A1 WO 2015072125A1 JP 2014005626 W JP2014005626 W JP 2014005626W WO 2015072125 A1 WO2015072125 A1 WO 2015072125A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- parvovirus
- group
- composition according
- composition
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Definitions
- the present invention relates to an antiviral composition, particularly to an antiviral composition against parvovirus.
- Parvovirus infection presents severe symptoms such as a rapid rise in body temperature, diarrhea, vomiting, and loss of appetite.
- the white blood cell count (WBC) also decreases rapidly.
- canine parvovirus is a highly resistant virus and can survive for months to years in a normal environment. Especially when reared as a group, it can be violent, and death from this infection in breeders and pet shops is a major problem.
- Patent Document 1 a vaccine against parvovirus infection has also been developed (for example, Patent Document 1), but such a parvovirus infection vaccine is not sufficient in its protective effect and has a side effect on the vaccine. Needed attention. Therefore, the simplest defense method is to prevent the entry of parvovirus.
- sodium hypochlorite is known as an effective drug against parvovirus.
- the remaining sodium hypochlorite is likely to cause damage to the trachea, etc., with respect to pets, etc., so it is difficult to sufficiently wipe off sodium hypochlorite adhering to the instrument. It was.
- antiviral compositions containing two or all of the components selected from the group consisting of ionic polyvalent metal components, cationic polymers and cationic surfactants are patented against influenza viruses. It is described in Document 2. Here, examples of compositions containing chitosan as the cationic polymer and benzalkonium chloride as the cationic surfactant are described.
- various virus infections such as adenoviruses, coronaviruses, parainfluenza viruses, rhinoviruses, respiratory syncytial viruses, herpes simplex viruses, and HIV infections are improved.
- viruses with envelopes can be easily destroyed when treated with ethanol, organic solvents, soap, etc., because most of the envelope consists of lipids. For this reason, it is difficult to inactivate viruses having no envelope such as parvoviruses, while influenza viruses having envelopes are easily inactivated with disinfecting alcohol.
- Patent Document 3 A composition containing ethanol, acetic acid, chitosan and a quaternary ammonium salt is also known as a toilet seat cleaner (Patent Document 3), a mastitis preventive agent for livestock (Patent Document 4), etc.
- Patent Document 5 discloses the antiviral properties of parvovirus by the combined use of acridine or an acridine derivative and benzalkonium chloride.
- acridine is suspected as a carcinogen, it cannot be used as an antiviral agent for pets.
- ethanol and acetic acid There is no description of ethanol and acetic acid. It was described that the use of benzalkonium chloride alone did not show antiviral properties against parvovirus.
- Patent Document 6 describes that a composition of a disinfecting alcohol and an organic acid can reduce non-enveloped viruses. Specifically, there is a description about a combination of a C1-C6 alcohol and a C1-C6 carboxylic acid. Nor is it described that parvovirus can be reduced. Therefore, the development of a substance that can easily inactivate parvovirus adhering to an instrument or the like is awaited.
- JP 2004-352893 A Special table 2007-513959 gazette Japanese Patent Laid-Open No. 11-1700 JP-A-6-56675 JP-A-8-225455 JP 2008-523066 A
- the present inventors have inactivated parvoviruses such as canine parvovirus by using a composition containing C1-C6 alcohol and C1-C6 carboxylic acid. As a result, the present invention has been completed.
- the present invention (1) An anti-parvovirus composition comprising 0.1 to 20% by mass of C1-C6 alcohol and 0.01 to 10% by mass of C1-C6 carboxylic acid based on the total amount of the composition, (2) The anti-parvovirus composition according to (1), wherein the C1-C6 alcohol is ethanol, (3) The anti-parvovirus composition according to (1) or (2), wherein the C1-C6 carboxylic acid is acetic acid, (4) The anti-parvovirus composition according to any one of (1) to (3), further comprising chitosan, a derivative thereof or a salt thereof, and (5) a quaternary ammonium salt system The anti-parvovirus composition according to any one of (1) to (4), which comprises a surfactant.
- the present invention also provides: (6) A bactericidal antiviral agent for pets comprising the anti-parvoviral composition according to any one of (1) to (5), (7) A fiber material comprising the anti-parvoviral composition according to any one of (1) to (5), (8) A cream comprising the anti-parvoviral composition according to any one of (1) to (5), and (9) the cream according to any one of (1) to (5)
- the present invention relates to an antibacterial antiviral film characterized by containing an antiparvoviral composition.
- composition of the present invention can inactivate parvoviruses such as canine parvovirus. Further, by containing a quaternary ammonium salt surfactant, chitosan, a derivative thereof or a salt thereof, the effect can be enhanced and the effect can be maintained. Therefore, the infection of the disease based on a parvovirus can be suppressed by apply
- anti-parvovirus means a medicinal effect that inactivates a virus, and as a result, indicates that the possibility of suffering from a parvoviral disease is reduced.
- parvovirus means a spherical animal virus having a linear single-stranded DNA belonging to the family Parvoviridae.
- the Parvoviridae includes the following subfamilies and genera:
- Parvovirinae Parvovirus Canine Parvovirus, Cat Parvovirus Feline Parvovirus, etc. Erythrovirus Parvovirus B19 Parvovirus B19 etc.
- parvovirus does not have an envelope. This means that even if the compound has an envelope, such as an influenza virus and is antiviral, a parvovirus can be inactivated unless a virus inactivation test is actually performed to confirm that the parvovirus can be inactivated. This indicates that it cannot be determined whether or not it has antiviral properties against viruses.
- the anti-parvovirus composition of the present invention targets all viruses belonging to the above-mentioned parvoviridae. Particularly, it is suitable for viruses belonging to the genus Parvovirus such as canine parvovirus and cat parvovirus.
- the anti-parvovirus agent of the present invention usually contains C1-C6 alcohol and C1-C6 carboxylic acid as essential components in a solvent such as water. Preferably, it further contains a quaternary ammonium salt surfactant and / or chitosan, a derivative thereof or a salt thereof.
- the C1 to C6 alcohol is not particularly limited, and the C1 to C6 alcohol concentration is 0.1 to 20% by mass, preferably 0.5 to 15% by mass, and more preferably, based on the total amount of the composition. 1.0 to 10% by mass.
- the C1 to C6 carboxylic acid is not particularly limited, and the C1 to C6 carboxylic acid concentration is 0.01 to 10% by mass, preferably 0.01 to 5% by mass, and more preferably 0%, based on the total amount of the composition. 0.01 to 3% by mass.
- C1 to C6 alcohols are alcohols having 1 to 6 carbon atoms, such as methanol, ethanol, n-propanol, i-propanol, n-butanol, sec-butanol, t-butanol, isobutanol, and n-pentanol.
- Isopentanol, neopentanol, t-pentanol, n-hexanol, isohexanol, 1-methylpentanol, 2-methylpentanol, and the like are exemplified, but ethanol is particularly preferable.
- C1-C6 carboxylic acid is a compound having a carboxyl group containing 1 to 6 carbon atoms including a carboxyl group (COOH), and monocarboxylic acids such as acetic acid, propionic acid, butyric acid, pentanoic acid, hexanoic acid, glycolic acid, etc. Examples thereof include dicarboxylic acids such as diglycolic acid, oxalic acid, maleic acid, tartaric acid, and succinic acid, and tricarboxylic acids such as citric acid, but acetic acid is particularly preferable.
- the anti-parvovirus composition of the present invention optionally comprises a quaternary ammonium surfactant, chitosan, a derivative thereof or a salt thereof, a humectant, a pH adjuster, a pH buffer, a viscosity adjuster, an osmotic agent, Flavor substances, sweeteners, preservatives, preservatives (for example, metal chelating agents), adhesives, colorants and the like can be included. However, acridine or acridine derivatives are not contained.
- Quaternary ammonium salt surfactant are, for example, those of the formula (I) And a mixture thereof.
- R 1 to R 4 each independently represents a linear or branched C1-C20 hydrocarbon group which may have an oxygen atom
- X ⁇ represents a counter ion.
- 1 or 2 of R 1 to R 4 is a linear or branched C8 to C18 hydrocarbon group which may have an oxygen atom
- 1 of R 1 to R 4 Is a benzyl group
- one or two of R 1 to R 4 are a C1-3 linear or branched alkyl group or a hydroxyalkyl group.
- the “C1-C20 hydrocarbon group” in the above-mentioned “linear or branched C1-C20 hydrocarbon group optionally having an oxygen atom” includes a C1-C20 alkyl group and a C2-C20 alkenyl group.
- Examples of the C1 to C20 alkyl group include methyl group, ethyl group, n-propyl group, i-propyl group, n-butyl group, s-butyl group, i-butyl group, t-butyl group, and n-pentyl group.
- Examples of the C2-C20 alkenyl group include vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-2-propenyl, 2-methyl -2-propenyl group, 1-pentenyl group, 2-pentenyl group, 3-pentenyl group, 4-pentenyl group, 1-methyl-2-butenyl group, 2-methyl-2-butenyl group, 1-hexenyl group, 2 -Hexenyl group, 3-hexenyl group, 4-hexenyl group, 5-hexenyl group, heptenyl group, octenyl group, decenyl group, pentadecenyl group, eicocenyl group and the like.
- the above C6 to C10 aryl group means a monocyclic or polycyclic aryl group.
- a partially saturated group is also included in addition to a fully unsaturated group. Examples thereof include a phenyl group, a naphthyl group, an azulenyl group, an indenyl group, an indanyl group, and a tetralinyl group.
- Examples of the composite group of the C1 to C20 alkyl group and the C6 to C10 aryl group include a benzyl group, a phenethyl group, a toluyl group, and a xylyl group.
- the “C8-C18 hydrocarbon group” of the above-mentioned “linear or branched C8-C18 hydrocarbon group optionally having an oxygen atom” includes an octyl group, an i-octyl group, and an s-octyl group. , T-octyl group, nonyl group, decyl group, undecyl group, dodecyl group, tridecyl group, tetradecyl group, pentadecyl group, hexadecyl group, heptadecyl group, octadecyl group, etc.
- C8-C18 alkyl group 1-methoxyheptadecyl group
- C8-C18 alkyl groups having an oxygen atom such as 1-methoxyethoxytetradecyl group and 1-methoxyethoxyethoxydodecyl group.
- Examples of X ⁇ include halogen ions, organic acid ions and inorganic acid ions.
- Halogen ions such as chloro ion and brom ion, organic sulfonate ions such as dimethyl sulfate and diethyl sulfate, formic acid, acetic acid and propion.
- Carboxylic acid ions such as acids are preferred.
- quaternary ammonium salt surfactant represented by the general formula (I) include benzalkonium chloride, benzethonium chloride, dimethylammonium chloride, and tetradecyldimethylbenzylammonium chloride. Although possible, benzalkonium chloride is particularly preferred. Benzalkonium chloride is represented by the general formula [C 6 H 5 CH 2 N (CH 3 ) 2 R] + Cl ⁇ (wherein R is an alkyl group having 8 to 18 carbon atoms). Quaternary ammonium salt.
- octyldimethylbenzylammonium chloride decyldimethylbenzylammonium chloride, dodecyldimethylbenzylammonium chloride, tetradecyldimethylbenzylammonium chloride, hexadecyldimethylbenzylammonium chloride, octadecyldimethylbenzylammonium chloride, cocoalkyldimethylbenzylammonium chloride, etc. Is mentioned. Tetradecyldimethylbenzylammonium chloride and cocoalkyldimethylbenzylammonium chloride are preferable.
- the content of the quaternary ammonium salt surfactant in the anti-parvovirus composition of the present invention is 0.001 to 50% by mass, preferably 0.01 to 10%, based on the total amount of the composition.
- Chitosan for example, shells of crab, shrimp, etc., insect hulls and other chitinous sources are finely ground, treated with dilute hydrochloric acid to remove calcium carbonate, and treated with an alkaline concentrated solution to remove proteins and other contaminants. It is a basic polysaccharide of white amorphous powder obtained by deacetylating chitin obtained by high-concentration alkali at a high temperature and having glucosamine as a repeating unit. Chitosan has a molecular weight of several thousands to several hundred thousand, but a lower molecular weight is desirable from the viewpoint of bactericidal effect.
- the degree of deacetylation is preferably 50% or more and 80% or more in consideration of water solubility and bacteriostatic effect.
- free chitosan itself is not soluble in water, it may be used as a chitosan salt which is treated with an inorganic acid or an organic acid and is soluble in water, or an inorganic acid such as hydrochloric acid or phosphoric acid, acetic acid, It may be dissolved in an organic acid such as lactic acid, citric acid or gluconic acid.
- Chitosan, a derivative thereof or a salt thereof can be added to the anti-parvovirus composition of the present invention. This can further enhance the antiviral effect of the quaternary ammonium salt.
- a natural film can be formed with chitosan. Thereby, an antiviral effect is exhibited continuously. It can be easily washed with water.
- the chitosan derivative used in the present invention includes all or part of the free amino group or hydroxyl group of chitosan, preferably an alkyl group (preferably a C1-C6 alkyl group), an alkoxyalkyl group (preferably a C1-C6 alkoxy C1-C6 alkyl).
- alkylthioalkyl group preferably C1-C6 alkylthio C1-C6 alkyl group
- aryl group preferably C6-C10 aryl group
- aralkyl group preferably C6-C10 aryl C1-C6 alkyl group
- acyl group Preferably a C1 to C6 acyl group
- a sulfonyl group an alkoxycarbonyl group (preferably a C1 to C6 alkoxycarbonyl group), a phosphoric acid residue or the like may be mentioned.
- the content of chitosan, a derivative thereof or a salt thereof in the anti-parvovirus composition of the present invention is 0.01 to 50% by mass, preferably 0.05 to 10% by mass with respect to the total amount of the composition.
- the degree of deacetylation is preferably 80% or more, and the viscosity of a 1% by mass acetic acid solution at 20 ° C. is 0.1 to 50 mPa ⁇ s.
- a humectant shows the component which has a function which maintains humidity, for example, glycerol etc. can be illustrated.
- the pH adjuster is added to adjust the pH of the solution to an appropriate value, and examples thereof include carboxylic acids such as acetic acid, lactic acid, and citric acid.
- the pH is preferably 3-6.
- the acridine derivative represents a compound having an acridine skeleton.
- Acridine is also known to be a carcinogenic substance. Therefore, it does not contain in this invention.
- the method for preparing the anti-parvovirus composition of the present invention is not particularly limited. For example, first, an appropriate amount of all components is dissolved in a solvent such as water, and a pH adjuster is added as necessary to adjust the pH. And add water to final weight. The composition can be further sterilized and stored in a suitable container.
- the anti-parvovirus composition of the present invention is applied to humans, animals, containers, pet supplies, etc. in the form of solutions, gels, suspensions, lotions, ointments, creams, tapes, etc. for humans and animals. can do.
- the anti-parvovirus composition of the present invention is a carrier made of a fiber material such as paper, gauze, absorbent cotton, or non-woven fabric, such as a towel, a rag, a cloth, an antibacterial film, a tissue paper, a wet tissue (registered trademark), a wet wiper. (Registered Trademark) or the like can be impregnated to wipe humans, animals, instruments and the like.
- anti-parvovirus composition of the present invention include pet antibacterial antiviral agents, fiber materials, creams, antibacterial antiviral membranes and the like containing the anti-parvovirus composition of the present invention.
- the pet disinfectant can contain the anti-parvovirus composition of the present invention.
- medicinal bactericides, disinfectants, and antibacterial agents cannot be used because they have strong irritation and smell to pets. Furthermore, even if it is effective against bacteria, it is not always effective against viruses.
- the anti-parvovirus composition of the present invention not only inactivates parvovirus but also has a bactericidal effect against various bacteria, it can be used as a bactericidal agent for pet equipment. . Furthermore, there is no irritation and no smell, and it can be used with confidence for pets. Sterilization means that it has the effect of killing bacteria.
- the medicine contained by wiping the pet equipment adheres to the equipment, and the virus attached to the equipment is inactivated by antiviral properties. Can do.
- bacteria, viruses and the like attached to the instrument can be entangled in the fiber material by the wiping operation.
- the anti-parvovirus composition remaining in the fiber material causes sterilization or virus inactivation, so that bacteria and viruses are not diffused when wiping other parts.
- bacteria and viruses attached to the pet's body hair can be removed by placing the anti-parvovirus composition solution of the present invention in a bucket or the like in advance, immersing and squeezing elephant, etc., and wiping the pet. The body odor can be reduced.
- the cream agent containing a cream-like anti-parvovirus component can be manufactured by stirring.
- This cream can be applied directly to the skin of a pet. This has the effect of softening the hard skin of the pet and facilitating penetration of the anti-parvovirus component into the skin.
- the anti-parvovirus agent persists for a long period of time due to the effect of the cream so that the anti-parvovirus agent remains on the skin for a long time.
- an antibacterial antiviral film By adding chitosan or a salt thereof, or a chitosan derivative or a salt thereof to the anti-parvovirus composition of the present invention, an antibacterial antiviral film can be prepared after application. Since this antibacterial antiviral film contains an anti-parvovirus component, it can inactivate bacteria and parvovirus and can maintain the state for a long time. Antibacterial means to suppress the generation, growth and proliferation of microorganisms.
- GIBCO is a registered trademark name.
- Benzalkonium chloride uses tetradecyldimethylbenzylammonium chloride manufactured by NOF Corporation, and chitosan has a viscosity of 10 mPa ⁇ s (1% by mass acetic acid solution, 20 ° C.) and a deacetylation degree of 90%.
- the present invention need not be limited to these raw materials.
- Canine parvovirus KMC91112 strain (CPV) was infected with MDCK cells (canine kidney cells; RCB0995 strain) and cultured at 37 ° C. in the presence of 5% CO 2 for 72 hours. Mass culture was performed after 5 consecutive passages. A part of the virus solution was confirmed for cytopathic effect by a 10-fold serial dilution method, and the virus infectivity titer (TCID 50 ) was measured.
- the measurement sample was serially diluted 10-fold, 100 ⁇ L of MDCK cells were inoculated, and contact-infected for 1 hour. After removing the measurement sample, 0.1 mL of virus maintenance medium 1% BSA-containing Eagle MEM (GIBCO) was added, and the mixture was cultured at 37 ° C. in the presence of 5% CO 2 for 96 hours. The cytopathic effect or metabolic inhibition was observed every 24 hours, and the virus infection titer (TCID50) was measured. Moreover, the virus suppression rate was computed by the following formula using the virus infection titer at the time of 1/1000 dilution at the time of MDCK seeding. For example, 10 minutes after Example 1, It becomes. The logarithm of TCID50 (unit: log TCID50 / mL) at the sensitization time of 10 minutes and 20 minutes is shown in Table 2, and the virus suppression rate (unit:%) is shown in Table 3.
- Example 3 Summary From the results of Example 1, it was found that the composition containing ethanol and acetic acid has an inactivating effect on parvovirus. From the result of Example 2, the effect increased by adding glycerin further. From the results of Examples 3 and 4, even when benzalkonium chloride or chitosan was further added, the effect was maintained.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention addresses the problem of providing an agent that is capable of inactivating a parvovirus adhering to an article for pet, etc. and sustaining the effect over a long period of time.
An anti-parvovirus composition according to the present invention contains 0.1-20 mass% of a C1-C6 alcohol and 0.01-10 mass% of a C1-C6 carboxylic acid.
As the C1-C6 alcohol, ethanol is preferred. As the C1-C6 carboxylic acid, acetic acid is preferred. It is preferred that the anti-parvovirus composition according to the present invention further contains chitosan, a derivative thereof or a salt thereof. It is still preferred that the anti-parvovirus composition further contains a quaternary ammonium salt-based surfactant.
Examples of the usage form of the anti-parvovirus composition according to the present invention include bactericidal and antiviral agents for pet, fiber materials, creams and antibacterial and antiviral films.
Description
本発明は、抗ウイルス組成物、特に、パルボウイルスに対する抗ウイルス組成物に関する。本願は、２０１３年１１月１４日に出願された日本国特許出願第２０１３－２３５７９９号に対し優先権を主張し、その内容をここに援用する。
The present invention relates to an antiviral composition, particularly to an antiviral composition against parvovirus. This application claims priority to Japanese Patent Application No. 2013-235799 filed on November 14, 2013, the contents of which are incorporated herein by reference.
パルボウイルス感染症は、体温の急激な上昇や、下痢、嘔吐、食欲廃絶など重篤な症状を呈する。白血球数（ＷＢＣ）も急激に減少する。例えば、イヌパルボウイルスは、非常に抵抗性の強いウイルスであり、通常の環境中で数ヶ月から数年間生存するため、自然発症例も少なくない。特に集団として飼育される場合は猛威を振るうことがあり、ブリーダーやペットショップでの本感染症による死亡が大きな問題となっている。
一般にウイルスに対する防御方法は、大きく分類して３種類ある。一つ目は、体内に抗生物質等を摂取してウイルスを死滅させること、二つ目は、予めワクチンを接種して体内に免疫を作ること、三つ目は、ウイルスを体内に取り込まないように接触する可能性のあるものを清潔に保つことである。しかし、抗生物質には副作用の懸念があり、子供やペットに対して使用しにくい。また、パルボウイルス感染症に対するワクチンも開発されている（たとえば、特許文献１）が、このようなパルボウイルス感染症ワクチンは、その防御効果が十分ではなく、ワクチンにも副作用があるため使用するには注意が必要であった。そのため、パルボウイルスを取り込まないようにすることが一番簡単な防御方法である。しかし、パルボウイルスに対する有効な薬品として次亜塩素酸ソーダが知られているが、ペット向け器具を次亜塩素酸ソーダ液に浸漬してパルボウイルスを除去しようとすると、次亜塩素酸ソーダにより器具の傷みが早くなり、さらに残存する次亜塩素酸ソーダがペット等に対して、気管への異常の懸念等があるため、器具に付着する次亜塩素酸ソーダを十分に拭き取る作業が大変であった。 Parvovirus infection presents severe symptoms such as a rapid rise in body temperature, diarrhea, vomiting, and loss of appetite. The white blood cell count (WBC) also decreases rapidly. For example, canine parvovirus is a highly resistant virus and can survive for months to years in a normal environment. Especially when reared as a group, it can be violent, and death from this infection in breeders and pet shops is a major problem.
In general, there are three types of virus protection methods. The first is to ingest antibiotics into the body to kill the virus, the second is to immunize the body by vaccination in advance, and the third is to prevent the virus from being taken into the body. Keeping things that may come in contact with clean. However, antibiotics have side effects and are difficult to use on children and pets. In addition, a vaccine against parvovirus infection has also been developed (for example, Patent Document 1), but such a parvovirus infection vaccine is not sufficient in its protective effect and has a side effect on the vaccine. Needed attention. Therefore, the simplest defense method is to prevent the entry of parvovirus. However, sodium hypochlorite is known as an effective drug against parvovirus. However, when trying to remove parvovirus by immersing pet equipment in sodium hypochlorite solution, The remaining sodium hypochlorite is likely to cause damage to the trachea, etc., with respect to pets, etc., so it is difficult to sufficiently wipe off sodium hypochlorite adhering to the instrument. It was.
一般にウイルスに対する防御方法は、大きく分類して３種類ある。一つ目は、体内に抗生物質等を摂取してウイルスを死滅させること、二つ目は、予めワクチンを接種して体内に免疫を作ること、三つ目は、ウイルスを体内に取り込まないように接触する可能性のあるものを清潔に保つことである。しかし、抗生物質には副作用の懸念があり、子供やペットに対して使用しにくい。また、パルボウイルス感染症に対するワクチンも開発されている（たとえば、特許文献１）が、このようなパルボウイルス感染症ワクチンは、その防御効果が十分ではなく、ワクチンにも副作用があるため使用するには注意が必要であった。そのため、パルボウイルスを取り込まないようにすることが一番簡単な防御方法である。しかし、パルボウイルスに対する有効な薬品として次亜塩素酸ソーダが知られているが、ペット向け器具を次亜塩素酸ソーダ液に浸漬してパルボウイルスを除去しようとすると、次亜塩素酸ソーダにより器具の傷みが早くなり、さらに残存する次亜塩素酸ソーダがペット等に対して、気管への異常の懸念等があるため、器具に付着する次亜塩素酸ソーダを十分に拭き取る作業が大変であった。 Parvovirus infection presents severe symptoms such as a rapid rise in body temperature, diarrhea, vomiting, and loss of appetite. The white blood cell count (WBC) also decreases rapidly. For example, canine parvovirus is a highly resistant virus and can survive for months to years in a normal environment. Especially when reared as a group, it can be violent, and death from this infection in breeders and pet shops is a major problem.
In general, there are three types of virus protection methods. The first is to ingest antibiotics into the body to kill the virus, the second is to immunize the body by vaccination in advance, and the third is to prevent the virus from being taken into the body. Keeping things that may come in contact with clean. However, antibiotics have side effects and are difficult to use on children and pets. In addition, a vaccine against parvovirus infection has also been developed (for example, Patent Document 1), but such a parvovirus infection vaccine is not sufficient in its protective effect and has a side effect on the vaccine. Needed attention. Therefore, the simplest defense method is to prevent the entry of parvovirus. However, sodium hypochlorite is known as an effective drug against parvovirus. However, when trying to remove parvovirus by immersing pet equipment in sodium hypochlorite solution, The remaining sodium hypochlorite is likely to cause damage to the trachea, etc., with respect to pets, etc., so it is difficult to sufficiently wipe off sodium hypochlorite adhering to the instrument. It was.
他方、インフルエンザウイルスに対しては、イオン性多価金属成分、陽イオン性ポリマーおよび陽イオン界面活性剤からなる群より選択される成分のうち２つまたはすべてを含む、抗ウイルス性組成物が特許文献２に記載されている。ここでは、陽イオン性ポリマーとしてキトサン、陽イオン界面活性剤として塩化ベンザルコニウムを含有する組成物の例が記載されている。
当該文献には、ウイルスとして、インフルエンザウイルス以外にも、アデノウイルス、コロナウイルス、パラインフルエンザウイルス、ライノウイルス、呼吸器合胞体ウイルス、単純ヘルペスウイルス、ＨＩＶなどによる感染症といった、さまざまなウイルス感染を改善するために用いることができるとも記載されているが、ウイルスは進化の系譜が細胞を有する生物とは著しく異なり、個々のウイルスの分子生物学的な形質の多様性は著しく高い。そのため、それぞれの生活環、転写因子が異なっており、それぞれに対する治療薬が必要となることが多く、上記組成物が、上記インフルエンザウイルスとは科の異なるパルボウイルスに効果があるかは不明である。
さらに、エンベロープを持っているウイルスは、エンベロープの大部分が脂質から成るため、エタノールや有機溶媒、石鹸などで処理すると容易に破壊することできる。このためエンベロープを持つインフルエンザウイルス等は、消毒用アルコールでの不活性化が容易であるのに対し、パルボウイルス等のエンベロープを持たないウイルスを不活性化するのが困難であった。
また、エタノール、酢酸、キトサンと第４級アンモニウム塩を含有する組成物は、便座クリーナー（特許文献３）、家畜の乳房炎予防剤（特許文献４）等としても知られているが、これらの文献には、パルボウイルスに効果があることは記載されていない。
また、特許文献５には、アクリジンまたはアクリジン誘導体と塩化ベンザルコニウムの併用によるパルボウイルスの抗ウイルス性を開示している。しかし、アクリジンは発がん性物質として疑われているため、ペット用の抗ウイルス剤に用いることができない。また、エタノールと酢酸の記載もない。なお、これには塩化ベンザルコニウム単独使用ではパルボウイルスに対して抗ウイルス性を示さないことが記載されていた。
特許文献６には、消毒用アルコールと有機酸の組成物が非エンベロープウイルスを減少されることが記載されているが、具体的にＣ１～Ｃ６アルコールとＣ１～Ｃ６カルボン酸の組み合わせについての記載はなく、また、パルボウイルスを減少できることも記載されていない。
したがって、器具などに付着したパルボウイルスを簡単に不活性化させる物質の開発が待たれている。 On the other hand, antiviral compositions containing two or all of the components selected from the group consisting of ionic polyvalent metal components, cationic polymers and cationic surfactants are patented against influenza viruses. It is described in Document 2. Here, examples of compositions containing chitosan as the cationic polymer and benzalkonium chloride as the cationic surfactant are described.
In this document, in addition to influenza viruses, various virus infections such as adenoviruses, coronaviruses, parainfluenza viruses, rhinoviruses, respiratory syncytial viruses, herpes simplex viruses, and HIV infections are improved. Although it is also described that the virus can be used to do so, the evolutionary lineage differs significantly from organisms with cells, and the diversity of the molecular biological traits of individual viruses is remarkably high. Therefore, each life cycle and transcription factor are different, and therapeutic drugs are often required for each, and it is unclear whether the above composition is effective against parvoviruses that are different from the above influenza viruses. .
Furthermore, viruses with envelopes can be easily destroyed when treated with ethanol, organic solvents, soap, etc., because most of the envelope consists of lipids. For this reason, it is difficult to inactivate viruses having no envelope such as parvoviruses, while influenza viruses having envelopes are easily inactivated with disinfecting alcohol.
A composition containing ethanol, acetic acid, chitosan and a quaternary ammonium salt is also known as a toilet seat cleaner (Patent Document 3), a mastitis preventive agent for livestock (Patent Document 4), etc. The literature does not mention that parvovirus is effective.
Patent Document 5 discloses the antiviral properties of parvovirus by the combined use of acridine or an acridine derivative and benzalkonium chloride. However, since acridine is suspected as a carcinogen, it cannot be used as an antiviral agent for pets. There is no description of ethanol and acetic acid. It was described that the use of benzalkonium chloride alone did not show antiviral properties against parvovirus.
Patent Document 6 describes that a composition of a disinfecting alcohol and an organic acid can reduce non-enveloped viruses. Specifically, there is a description about a combination of a C1-C6 alcohol and a C1-C6 carboxylic acid. Nor is it described that parvovirus can be reduced.
Therefore, the development of a substance that can easily inactivate parvovirus adhering to an instrument or the like is awaited.
当該文献には、ウイルスとして、インフルエンザウイルス以外にも、アデノウイルス、コロナウイルス、パラインフルエンザウイルス、ライノウイルス、呼吸器合胞体ウイルス、単純ヘルペスウイルス、ＨＩＶなどによる感染症といった、さまざまなウイルス感染を改善するために用いることができるとも記載されているが、ウイルスは進化の系譜が細胞を有する生物とは著しく異なり、個々のウイルスの分子生物学的な形質の多様性は著しく高い。そのため、それぞれの生活環、転写因子が異なっており、それぞれに対する治療薬が必要となることが多く、上記組成物が、上記インフルエンザウイルスとは科の異なるパルボウイルスに効果があるかは不明である。
さらに、エンベロープを持っているウイルスは、エンベロープの大部分が脂質から成るため、エタノールや有機溶媒、石鹸などで処理すると容易に破壊することできる。このためエンベロープを持つインフルエンザウイルス等は、消毒用アルコールでの不活性化が容易であるのに対し、パルボウイルス等のエンベロープを持たないウイルスを不活性化するのが困難であった。
また、エタノール、酢酸、キトサンと第４級アンモニウム塩を含有する組成物は、便座クリーナー（特許文献３）、家畜の乳房炎予防剤（特許文献４）等としても知られているが、これらの文献には、パルボウイルスに効果があることは記載されていない。
また、特許文献５には、アクリジンまたはアクリジン誘導体と塩化ベンザルコニウムの併用によるパルボウイルスの抗ウイルス性を開示している。しかし、アクリジンは発がん性物質として疑われているため、ペット用の抗ウイルス剤に用いることができない。また、エタノールと酢酸の記載もない。なお、これには塩化ベンザルコニウム単独使用ではパルボウイルスに対して抗ウイルス性を示さないことが記載されていた。
特許文献６には、消毒用アルコールと有機酸の組成物が非エンベロープウイルスを減少されることが記載されているが、具体的にＣ１～Ｃ６アルコールとＣ１～Ｃ６カルボン酸の組み合わせについての記載はなく、また、パルボウイルスを減少できることも記載されていない。
したがって、器具などに付着したパルボウイルスを簡単に不活性化させる物質の開発が待たれている。 On the other hand, antiviral compositions containing two or all of the components selected from the group consisting of ionic polyvalent metal components, cationic polymers and cationic surfactants are patented against influenza viruses. It is described in Document 2. Here, examples of compositions containing chitosan as the cationic polymer and benzalkonium chloride as the cationic surfactant are described.
In this document, in addition to influenza viruses, various virus infections such as adenoviruses, coronaviruses, parainfluenza viruses, rhinoviruses, respiratory syncytial viruses, herpes simplex viruses, and HIV infections are improved. Although it is also described that the virus can be used to do so, the evolutionary lineage differs significantly from organisms with cells, and the diversity of the molecular biological traits of individual viruses is remarkably high. Therefore, each life cycle and transcription factor are different, and therapeutic drugs are often required for each, and it is unclear whether the above composition is effective against parvoviruses that are different from the above influenza viruses. .
Furthermore, viruses with envelopes can be easily destroyed when treated with ethanol, organic solvents, soap, etc., because most of the envelope consists of lipids. For this reason, it is difficult to inactivate viruses having no envelope such as parvoviruses, while influenza viruses having envelopes are easily inactivated with disinfecting alcohol.
A composition containing ethanol, acetic acid, chitosan and a quaternary ammonium salt is also known as a toilet seat cleaner (Patent Document 3), a mastitis preventive agent for livestock (Patent Document 4), etc. The literature does not mention that parvovirus is effective.
Patent Document 5 discloses the antiviral properties of parvovirus by the combined use of acridine or an acridine derivative and benzalkonium chloride. However, since acridine is suspected as a carcinogen, it cannot be used as an antiviral agent for pets. There is no description of ethanol and acetic acid. It was described that the use of benzalkonium chloride alone did not show antiviral properties against parvovirus.
Patent Document 6 describes that a composition of a disinfecting alcohol and an organic acid can reduce non-enveloped viruses. Specifically, there is a description about a combination of a C1-C6 alcohol and a C1-C6 carboxylic acid. Nor is it described that parvovirus can be reduced.
Therefore, the development of a substance that can easily inactivate parvovirus adhering to an instrument or the like is awaited.
ペット用器具等に付着したパルボウイルスを不活性化し、さらにはその効果を長期間持続することができる剤を提供することを課題とする。
It is an object of the present invention to provide an agent that can inactivate parvovirus adhering to pet equipment and the like and can maintain its effect for a long period of time.
本発明者らは、上記課題を解決するために鋭意研究した結果、Ｃ１～Ｃ６アルコールとＣ１～Ｃ６カルボン酸を含有する組成物を使用することにより、イヌパルボウイルス等のパルボウイルスを不活性化することを見出し、本発明を完成するに至った。
As a result of intensive studies to solve the above problems, the present inventors have inactivated parvoviruses such as canine parvovirus by using a composition containing C1-C6 alcohol and C1-C6 carboxylic acid. As a result, the present invention has been completed.
すなわち本発明は、
（１）組成物全量に対して０．１～２０質量％のＣ１～Ｃ６アルコールと０．０１～１０質量％のＣ１～Ｃ６カルボン酸を含有することを特徴とする抗パルボウイルス組成物、
（２）前記Ｃ１～Ｃ６アルコールがエタノールであることを特徴とする（１）に記載の抗パルボウイルス組成物、
（３）前記Ｃ１～Ｃ６カルボン酸が酢酸であることを特徴とする（１）又は（２）に記載の抗パルボウイルス組成物、
（４）さらにキトサン、その誘導体又はそれらの塩を含有することを特徴とする（１）～（３）のいずれかに記載の抗パルボウイルス組成物、及び
（５）さらに第四級アンモニウム塩系界面活性剤を含有することを特徴とする（１）～（４）のいずれかに記載の抗パルボウイルス組成物に関する。 That is, the present invention
(1) An anti-parvovirus composition comprising 0.1 to 20% by mass of C1-C6 alcohol and 0.01 to 10% by mass of C1-C6 carboxylic acid based on the total amount of the composition,
(2) The anti-parvovirus composition according to (1), wherein the C1-C6 alcohol is ethanol,
(3) The anti-parvovirus composition according to (1) or (2), wherein the C1-C6 carboxylic acid is acetic acid,
(4) The anti-parvovirus composition according to any one of (1) to (3), further comprising chitosan, a derivative thereof or a salt thereof, and (5) a quaternary ammonium salt system The anti-parvovirus composition according to any one of (1) to (4), which comprises a surfactant.
（１）組成物全量に対して０．１～２０質量％のＣ１～Ｃ６アルコールと０．０１～１０質量％のＣ１～Ｃ６カルボン酸を含有することを特徴とする抗パルボウイルス組成物、
（２）前記Ｃ１～Ｃ６アルコールがエタノールであることを特徴とする（１）に記載の抗パルボウイルス組成物、
（３）前記Ｃ１～Ｃ６カルボン酸が酢酸であることを特徴とする（１）又は（２）に記載の抗パルボウイルス組成物、
（４）さらにキトサン、その誘導体又はそれらの塩を含有することを特徴とする（１）～（３）のいずれかに記載の抗パルボウイルス組成物、及び
（５）さらに第四級アンモニウム塩系界面活性剤を含有することを特徴とする（１）～（４）のいずれかに記載の抗パルボウイルス組成物に関する。 That is, the present invention
(1) An anti-parvovirus composition comprising 0.1 to 20% by mass of C1-C6 alcohol and 0.01 to 10% by mass of C1-C6 carboxylic acid based on the total amount of the composition,
(2) The anti-parvovirus composition according to (1), wherein the C1-C6 alcohol is ethanol,
(3) The anti-parvovirus composition according to (1) or (2), wherein the C1-C6 carboxylic acid is acetic acid,
(4) The anti-parvovirus composition according to any one of (1) to (3), further comprising chitosan, a derivative thereof or a salt thereof, and (5) a quaternary ammonium salt system The anti-parvovirus composition according to any one of (1) to (4), which comprises a surfactant.
また、本発明は、
（６）（１）～（５）のいずれかに記載の抗パルボウイルス性組成物を含有することを特徴とするペット用殺菌抗ウイルス剤、
（７）（１）～（５）のいずれかに記載の抗パルボウイルス性組成物を含有することを特徴とする繊維素材、
（８）（１）～（５）のいずれかに記載の抗パルボウイルス性組成物を含有することを特徴とするクリーム剤、及び
（９）（１）～（５）のいずれかに記載の抗パルボウイルス性組成物を含有することを特徴とする抗菌抗ウイルス膜に関する。 The present invention also provides:
(6) A bactericidal antiviral agent for pets comprising the anti-parvoviral composition according to any one of (1) to (5),
(7) A fiber material comprising the anti-parvoviral composition according to any one of (1) to (5),
(8) A cream comprising the anti-parvoviral composition according to any one of (1) to (5), and (9) the cream according to any one of (1) to (5) The present invention relates to an antibacterial antiviral film characterized by containing an antiparvoviral composition.
（６）（１）～（５）のいずれかに記載の抗パルボウイルス性組成物を含有することを特徴とするペット用殺菌抗ウイルス剤、
（７）（１）～（５）のいずれかに記載の抗パルボウイルス性組成物を含有することを特徴とする繊維素材、
（８）（１）～（５）のいずれかに記載の抗パルボウイルス性組成物を含有することを特徴とするクリーム剤、及び
（９）（１）～（５）のいずれかに記載の抗パルボウイルス性組成物を含有することを特徴とする抗菌抗ウイルス膜に関する。 The present invention also provides:
(6) A bactericidal antiviral agent for pets comprising the anti-parvoviral composition according to any one of (1) to (5),
(7) A fiber material comprising the anti-parvoviral composition according to any one of (1) to (5),
(8) A cream comprising the anti-parvoviral composition according to any one of (1) to (5), and (9) the cream according to any one of (1) to (5) The present invention relates to an antibacterial antiviral film characterized by containing an antiparvoviral composition.
本発明の組成物は、イヌパルボウイルス等のパルボウイルスを不活性化させることができる。さらに第四級アンモニウム塩系界面活性剤、キトサン、その誘導体又はそれらの塩を含有することによりその効果を高めると共に効果を持続させることができる。そのため、ヒト、動物等の皮膚や毛に塗布、噴霧したり、ペット用品に塗布したりすることにより、パルボウイルスに基づく疾患の感染を抑制することができる。
The composition of the present invention can inactivate parvoviruses such as canine parvovirus. Further, by containing a quaternary ammonium salt surfactant, chitosan, a derivative thereof or a salt thereof, the effect can be enhanced and the effect can be maintained. Therefore, the infection of the disease based on a parvovirus can be suppressed by apply | coating and spraying on skin and hair, such as a human and an animal, or applying to pet goods.
（抗パルボウイルス性）
本発明において、「抗パルボウイルス性」とは、ウイルスを不活性化する薬効のことを表し、その結果として、パルボウイルス性疾患に罹患する可能性を低下させることを示している。 (Anti-parvovirus)
In the present invention, the term “anti-parvovirus” means a medicinal effect that inactivates a virus, and as a result, indicates that the possibility of suffering from a parvoviral disease is reduced.
本発明において、「抗パルボウイルス性」とは、ウイルスを不活性化する薬効のことを表し、その結果として、パルボウイルス性疾患に罹患する可能性を低下させることを示している。 (Anti-parvovirus)
In the present invention, the term “anti-parvovirus” means a medicinal effect that inactivates a virus, and as a result, indicates that the possibility of suffering from a parvoviral disease is reduced.
（パルボウイルス）
本発明において、「パルボウイルス」とはパルボウイルス科 Parvoviridae に属する線状一本鎖ＤＮＡをもつ球状の動物ウイルスを意味する。
パルボウイルス科には、以下の亜科及び属が挙げられる。 (Parvovirus)
In the present invention, “parvovirus” means a spherical animal virus having a linear single-stranded DNA belonging to the family Parvoviridae.
The Parvoviridae includes the following subfamilies and genera:
本発明において、「パルボウイルス」とはパルボウイルス科 Parvoviridae に属する線状一本鎖ＤＮＡをもつ球状の動物ウイルスを意味する。
パルボウイルス科には、以下の亜科及び属が挙げられる。 (Parvovirus)
In the present invention, “parvovirus” means a spherical animal virus having a linear single-stranded DNA belonging to the family Parvoviridae.
The Parvoviridae includes the following subfamilies and genera:
・パルボウイルス亜科 Parvovirinae
パルボウイルス属Parvovirus
犬パルボウイルスCanine Parvovirus、猫パルボウイルス Feline Parvovirus 等
エリスロウイルス属Erythrovirus
パルボウイルスB19 Parvovirus B19 等
ディペンドウイルス属Dependovirus
アデノ随伴ウイルスAdeno-associated virus 等
・デンソ(濃核病）ウイルス亜科 Densovirinae
デンソウイルス属Densovirus
イテラウイルス属Iteravirus
ブレビデンソウイルス属Aedes aegypti densovirus ・ Parvovirinae
Parvovirus
Canine Parvovirus, Cat Parvovirus Feline Parvovirus, etc. Erythrovirus
Parvovirus B19 Parvovirus B19 etc. Dependovirus Dependovirus
Adeno-associated virus, etc., Densovirinae virus subfamily Densovirinae
Densovirus
Iteravirus
Aedes aegypti densovirus
パルボウイルス属Parvovirus
犬パルボウイルスCanine Parvovirus、猫パルボウイルス Feline Parvovirus 等
エリスロウイルス属Erythrovirus
パルボウイルスB19 Parvovirus B19 等
ディペンドウイルス属Dependovirus
アデノ随伴ウイルスAdeno-associated virus 等
・デンソ(濃核病）ウイルス亜科 Densovirinae
デンソウイルス属Densovirus
イテラウイルス属Iteravirus
ブレビデンソウイルス属Aedes aegypti densovirus ・ Parvovirinae
Parvovirus
Canine Parvovirus, Cat Parvovirus Feline Parvovirus, etc. Erythrovirus
Parvovirus B19 Parvovirus B19 etc. Dependovirus Dependovirus
Adeno-associated virus, etc., Densovirinae virus subfamily Densovirinae
Densovirus
Iteravirus
Aedes aegypti densovirus
また、パルボウイルスはエンベロープを持っていない。このことは、エンベロープを持っている、例えばインフルエンザウイルスで抗ウイルス性がある化合物であっても、実際にウイルス不活性化試験を実施して、パルボウイルスを不活性化できることを確認しない限り、パルボウイルスに対する抗ウイルス性を有するかどうかを判断することができないことを示している。
In addition, parvovirus does not have an envelope. This means that even if the compound has an envelope, such as an influenza virus and is antiviral, a parvovirus can be inactivated unless a virus inactivation test is actually performed to confirm that the parvovirus can be inactivated. This indicates that it cannot be determined whether or not it has antiviral properties against viruses.
（抗パルボウイルス組成物）
本発明の抗パルボウイルス組成物は、上記パルボウイルス科に属するすべてのウイルスを対象とする。
特に、犬パルボウイルス、猫パルボウイルス等のパルボウイルス属に属するウイルスに対して好適である。
本発明の抗パルボウイルス剤は、通常水等の溶媒中にＣ１～Ｃ６アルコールとＣ１～Ｃ６カルボン酸を必須成分として含有する。好ましくは、さらに第四級アンモニウム塩系界面活性剤、及び／又は、キトサン、その誘導体又はそれらの塩を含有する。
Ｃ１～Ｃ６アルコールは特に限定されるものではなくＣ１～Ｃ６アルコール濃度は、組成物全量に対して０．１～２０質量％であり、好ましくは、０．５～１５質量％、さらに好ましくは、１．０～１０質量％である。
Ｃ１～Ｃ６カルボン酸は特に限定されるものではなく、Ｃ１～Ｃ６カルボン酸濃度は、組成物全量に対して０．０１～１０質量％、好ましくは０．０１～５質量％、さらに好ましくは０．０１～３質量％である。 (Anti-parvovirus composition)
The anti-parvovirus composition of the present invention targets all viruses belonging to the above-mentioned parvoviridae.
Particularly, it is suitable for viruses belonging to the genus Parvovirus such as canine parvovirus and cat parvovirus.
The anti-parvovirus agent of the present invention usually contains C1-C6 alcohol and C1-C6 carboxylic acid as essential components in a solvent such as water. Preferably, it further contains a quaternary ammonium salt surfactant and / or chitosan, a derivative thereof or a salt thereof.
The C1 to C6 alcohol is not particularly limited, and the C1 to C6 alcohol concentration is 0.1 to 20% by mass, preferably 0.5 to 15% by mass, and more preferably, based on the total amount of the composition. 1.0 to 10% by mass.
The C1 to C6 carboxylic acid is not particularly limited, and the C1 to C6 carboxylic acid concentration is 0.01 to 10% by mass, preferably 0.01 to 5% by mass, and more preferably 0%, based on the total amount of the composition. 0.01 to 3% by mass.
本発明の抗パルボウイルス組成物は、上記パルボウイルス科に属するすべてのウイルスを対象とする。
特に、犬パルボウイルス、猫パルボウイルス等のパルボウイルス属に属するウイルスに対して好適である。
本発明の抗パルボウイルス剤は、通常水等の溶媒中にＣ１～Ｃ６アルコールとＣ１～Ｃ６カルボン酸を必須成分として含有する。好ましくは、さらに第四級アンモニウム塩系界面活性剤、及び／又は、キトサン、その誘導体又はそれらの塩を含有する。
Ｃ１～Ｃ６アルコールは特に限定されるものではなくＣ１～Ｃ６アルコール濃度は、組成物全量に対して０．１～２０質量％であり、好ましくは、０．５～１５質量％、さらに好ましくは、１．０～１０質量％である。
Ｃ１～Ｃ６カルボン酸は特に限定されるものではなく、Ｃ１～Ｃ６カルボン酸濃度は、組成物全量に対して０．０１～１０質量％、好ましくは０．０１～５質量％、さらに好ましくは０．０１～３質量％である。 (Anti-parvovirus composition)
The anti-parvovirus composition of the present invention targets all viruses belonging to the above-mentioned parvoviridae.
Particularly, it is suitable for viruses belonging to the genus Parvovirus such as canine parvovirus and cat parvovirus.
The anti-parvovirus agent of the present invention usually contains C1-C6 alcohol and C1-C6 carboxylic acid as essential components in a solvent such as water. Preferably, it further contains a quaternary ammonium salt surfactant and / or chitosan, a derivative thereof or a salt thereof.
The C1 to C6 alcohol is not particularly limited, and the C1 to C6 alcohol concentration is 0.1 to 20% by mass, preferably 0.5 to 15% by mass, and more preferably, based on the total amount of the composition. 1.0 to 10% by mass.
The C1 to C6 carboxylic acid is not particularly limited, and the C1 to C6 carboxylic acid concentration is 0.01 to 10% by mass, preferably 0.01 to 5% by mass, and more preferably 0%, based on the total amount of the composition. 0.01 to 3% by mass.
（Ｃ１～Ｃ６アルコール）
Ｃ１～Ｃ６アルコールとは、炭素数が１～６のアルコール類であり、メタノール、エタノール、ｎ－プロパノール、ｉ－プロパノール、ｎ－ブタノール、ｓｅｃ－ブタノール、ｔ－ブタノール、イソブタノール、ｎ－ペンタノール、イソペンタノール、ネオペンタノール、ｔ－ペンタノール、ｎ－ヘキサノール、イソヘキサノール、１－メチルペンタノール、又は２－メチルペンタノール等を例示することができるが、エタノールが特に良好である。 (C1-C6 alcohol)
C1 to C6 alcohols are alcohols having 1 to 6 carbon atoms, such as methanol, ethanol, n-propanol, i-propanol, n-butanol, sec-butanol, t-butanol, isobutanol, and n-pentanol. , Isopentanol, neopentanol, t-pentanol, n-hexanol, isohexanol, 1-methylpentanol, 2-methylpentanol, and the like are exemplified, but ethanol is particularly preferable.
Ｃ１～Ｃ６アルコールとは、炭素数が１～６のアルコール類であり、メタノール、エタノール、ｎ－プロパノール、ｉ－プロパノール、ｎ－ブタノール、ｓｅｃ－ブタノール、ｔ－ブタノール、イソブタノール、ｎ－ペンタノール、イソペンタノール、ネオペンタノール、ｔ－ペンタノール、ｎ－ヘキサノール、イソヘキサノール、１－メチルペンタノール、又は２－メチルペンタノール等を例示することができるが、エタノールが特に良好である。 (C1-C6 alcohol)
C1 to C6 alcohols are alcohols having 1 to 6 carbon atoms, such as methanol, ethanol, n-propanol, i-propanol, n-butanol, sec-butanol, t-butanol, isobutanol, and n-pentanol. , Isopentanol, neopentanol, t-pentanol, n-hexanol, isohexanol, 1-methylpentanol, 2-methylpentanol, and the like are exemplified, but ethanol is particularly preferable.
（Ｃ１～Ｃ６カルボン酸）
Ｃ１～Ｃ６カルボン酸とは、カルボキシル基（ＣＯＯＨ）を含む炭素数が１～６のカルボキシル基を有する化合物であり、酢酸、プロピオン酸、酪酸、ペンタン酸、ヘキサン酸、グリコール酸等のモノカルボン酸類、ジグリコール酸、シュウ酸、マレイン酸、酒石酸、コハク酸等のジカルボン酸類、クエン酸等のトリカルボン酸類等を例示することができるが、酢酸が特に良好である。 (C1-C6 carboxylic acid)
C1-C6 carboxylic acid is a compound having a carboxyl group containing 1 to 6 carbon atoms including a carboxyl group (COOH), and monocarboxylic acids such as acetic acid, propionic acid, butyric acid, pentanoic acid, hexanoic acid, glycolic acid, etc. Examples thereof include dicarboxylic acids such as diglycolic acid, oxalic acid, maleic acid, tartaric acid, and succinic acid, and tricarboxylic acids such as citric acid, but acetic acid is particularly preferable.
Ｃ１～Ｃ６カルボン酸とは、カルボキシル基（ＣＯＯＨ）を含む炭素数が１～６のカルボキシル基を有する化合物であり、酢酸、プロピオン酸、酪酸、ペンタン酸、ヘキサン酸、グリコール酸等のモノカルボン酸類、ジグリコール酸、シュウ酸、マレイン酸、酒石酸、コハク酸等のジカルボン酸類、クエン酸等のトリカルボン酸類等を例示することができるが、酢酸が特に良好である。 (C1-C6 carboxylic acid)
C1-C6 carboxylic acid is a compound having a carboxyl group containing 1 to 6 carbon atoms including a carboxyl group (COOH), and monocarboxylic acids such as acetic acid, propionic acid, butyric acid, pentanoic acid, hexanoic acid, glycolic acid, etc. Examples thereof include dicarboxylic acids such as diglycolic acid, oxalic acid, maleic acid, tartaric acid, and succinic acid, and tricarboxylic acids such as citric acid, but acetic acid is particularly preferable.
（その他の任意の成分）
本発明の抗パルボウイルス組成物は、任意で、第四級アンモニウム系界面活性剤、キトサン、その誘導体又はそれらの塩、保湿剤、ｐＨ調整剤、ｐＨ緩衝剤、粘度調整剤、浸透圧剤、香味物質、甘味料、防腐剤、保存料（例えば、金属キレート剤）、接着剤、着色剤等を含有させることができる。
但し、アクリジン又はアクリジン誘導体は含有しない。 (Other optional ingredients)
The anti-parvovirus composition of the present invention optionally comprises a quaternary ammonium surfactant, chitosan, a derivative thereof or a salt thereof, a humectant, a pH adjuster, a pH buffer, a viscosity adjuster, an osmotic agent, Flavor substances, sweeteners, preservatives, preservatives (for example, metal chelating agents), adhesives, colorants and the like can be included.
However, acridine or acridine derivatives are not contained.
本発明の抗パルボウイルス組成物は、任意で、第四級アンモニウム系界面活性剤、キトサン、その誘導体又はそれらの塩、保湿剤、ｐＨ調整剤、ｐＨ緩衝剤、粘度調整剤、浸透圧剤、香味物質、甘味料、防腐剤、保存料（例えば、金属キレート剤）、接着剤、着色剤等を含有させることができる。
但し、アクリジン又はアクリジン誘導体は含有しない。 (Other optional ingredients)
The anti-parvovirus composition of the present invention optionally comprises a quaternary ammonium surfactant, chitosan, a derivative thereof or a salt thereof, a humectant, a pH adjuster, a pH buffer, a viscosity adjuster, an osmotic agent, Flavor substances, sweeteners, preservatives, preservatives (for example, metal chelating agents), adhesives, colorants and the like can be included.
However, acridine or acridine derivatives are not contained.
（第四級アンモニウム塩系界面活性剤）
第四級アンモニウム塩系界面活性剤は、例えば、式（Ｉ）
で表される化合物及びそれらの混合物が挙げられる。
上記式（Ｉ）中、Ｒ１～Ｒ４は、それぞれ独立して、酸素原子を有していても良い直鎖又は分岐鎖のＣ１～Ｃ２０の炭化水素基を表し、Ｘ－は対イオンを表す。
好ましくは、Ｒ１～Ｒ４のうち、１又は２個は、酸素原子を有していても良い直鎖又は分岐鎖のＣ８～Ｃ１８の炭化水素基であり、Ｒ１～Ｒ４のうち１個は、ベンジル基であり、Ｒ１～Ｒ４のうち１又は２個は、Ｃ１～３の直鎖又は分岐鎖のアルキル基又はヒドロキシアルキル基である。 (Quaternary ammonium salt surfactant)
Quaternary ammonium salt surfactants are, for example, those of the formula (I)
And a mixture thereof.
In the above formula (I), R 1 to R 4 each independently represents a linear or branched C1-C20 hydrocarbon group which may have an oxygen atom, and X − represents a counter ion. To express.
Preferably, 1 or 2 of R 1 to R 4 is a linear or branched C8 to C18 hydrocarbon group which may have an oxygen atom, and 1 of R 1 to R 4 Is a benzyl group, and one or two of R 1 to R 4 are a C1-3 linear or branched alkyl group or a hydroxyalkyl group.
第四級アンモニウム塩系界面活性剤は、例えば、式（Ｉ）
上記式（Ｉ）中、Ｒ１～Ｒ４は、それぞれ独立して、酸素原子を有していても良い直鎖又は分岐鎖のＣ１～Ｃ２０の炭化水素基を表し、Ｘ－は対イオンを表す。
好ましくは、Ｒ１～Ｒ４のうち、１又は２個は、酸素原子を有していても良い直鎖又は分岐鎖のＣ８～Ｃ１８の炭化水素基であり、Ｒ１～Ｒ４のうち１個は、ベンジル基であり、Ｒ１～Ｒ４のうち１又は２個は、Ｃ１～３の直鎖又は分岐鎖のアルキル基又はヒドロキシアルキル基である。 (Quaternary ammonium salt surfactant)
Quaternary ammonium salt surfactants are, for example, those of the formula (I)
In the above formula (I), R 1 to R 4 each independently represents a linear or branched C1-C20 hydrocarbon group which may have an oxygen atom, and X − represents a counter ion. To express.
Preferably, 1 or 2 of R 1 to R 4 is a linear or branched C8 to C18 hydrocarbon group which may have an oxygen atom, and 1 of R 1 to R 4 Is a benzyl group, and one or two of R 1 to R 4 are a C1-3 linear or branched alkyl group or a hydroxyalkyl group.
上記「酸素原子を有していても良い直鎖又は分岐鎖のＣ１～Ｃ２０の炭化水素基」の「Ｃ１～Ｃ２０の炭化水素基」としては、Ｃ１～Ｃ２０のアルキル基、Ｃ２～Ｃ２０のアルケニル基、Ｃ６～Ｃ１０のアリール基、Ｃ１～Ｃ２０のアルキル基とＣ６～Ｃ１０のアリール基の複合基等が挙げられる。
The “C1-C20 hydrocarbon group” in the above-mentioned “linear or branched C1-C20 hydrocarbon group optionally having an oxygen atom” includes a C1-C20 alkyl group and a C2-C20 alkenyl group. Groups, C6 to C10 aryl groups, C1 to C20 alkyl groups and C6 to C10 aryl groups.
上記Ｃ１～Ｃ２０のアルキル基としては、メチル基、エチル基、ｎ－プロピル基、ｉ－プロピル基、ｎ－ブチル基、ｓ－ブチル基、ｉ－ブチル基、ｔ－ブチル基、ｎ－ペンチル基、ｎ－ヘキシル基、ｎ－ノニル基、ｉ－ノニル基、ｎ－デシル基、ｎ－ラウリル基、ｎ－トリデシル基、ミリスチル基、ｎ－ペンタデシル基、パルミチル基、ｎ－ヘプタデシル基、ステアリル基等が挙げられる。
Examples of the C1 to C20 alkyl group include methyl group, ethyl group, n-propyl group, i-propyl group, n-butyl group, s-butyl group, i-butyl group, t-butyl group, and n-pentyl group. N-hexyl group, n-nonyl group, i-nonyl group, n-decyl group, n-lauryl group, n-tridecyl group, myristyl group, n-pentadecyl group, palmityl group, n-heptadecyl group, stearyl group, etc. Is mentioned.
上記Ｃ２～Ｃ２０のアルケニル基としては、ビニル基、１－プロペニル基、２－プロペニル基、１－ブテニル基、２－ブテニル基、３－ブテニル基、１－メチル－２－プロペニル基、２－メチル－２－プロペニル基、１－ペンテニル基、２－ペンテニル基、３－ペンテニル基、４－ペンテニル基、１－メチル－２－ブテニル基、２－メチル－２－ブテニル基、１－ヘキセニル基、２－ヘキセニル基、３－ヘキセニル基、４－ヘキセニル基、５－ヘキセニル基、ヘプテニル基、オクテニル基、デセニル基、ぺンタデセニル基、エイコセニル基等が挙げられる。
Examples of the C2-C20 alkenyl group include vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-2-propenyl, 2-methyl -2-propenyl group, 1-pentenyl group, 2-pentenyl group, 3-pentenyl group, 4-pentenyl group, 1-methyl-2-butenyl group, 2-methyl-2-butenyl group, 1-hexenyl group, 2 -Hexenyl group, 3-hexenyl group, 4-hexenyl group, 5-hexenyl group, heptenyl group, octenyl group, decenyl group, pentadecenyl group, eicocenyl group and the like.
上記Ｃ６～Ｃ１０のアリール基は、単環又は多環のアリール基を意味し、多環アリール基の場合は、完全不飽和に加え、部分飽和の基も包含する。例えばフェニル基、ナフチル基、アズレニル基、インデニル基、インダニル基、テトラリニル基等が挙げられる。
The above C6 to C10 aryl group means a monocyclic or polycyclic aryl group. In the case of a polycyclic aryl group, a partially saturated group is also included in addition to a fully unsaturated group. Examples thereof include a phenyl group, a naphthyl group, an azulenyl group, an indenyl group, an indanyl group, and a tetralinyl group.
上記Ｃ１～Ｃ２０のアルキル基とＣ６～Ｃ１０のアリール基の複合基としては、ベンジル基、フェネチル基、トルイル基、キシリル基等が挙げられる。
Examples of the composite group of the C1 to C20 alkyl group and the C6 to C10 aryl group include a benzyl group, a phenethyl group, a toluyl group, and a xylyl group.
上記「酸素原子を有していても良い直鎖又は分岐鎖のＣ８～Ｃ１８の炭化水素基」の「Ｃ８～Ｃ１８の炭化水素基」としては、オクチル基、ｉ－オクチル基、ｓ－オクチル基、ｔ－オクチル基、ノニル基、デシル基、ウンデシル基、ドデシル基、トリデシル基、テトラデシル基、ペンタデシル基、ヘキサデシル基、ヘプタデシル基、オクタデシル基等のＣ８～Ｃ１８のアルキル基、１－メトキシヘプタデシル基、１－メトキシエトキシテトラデシル基、１－メトキシエトキシエトキシドデシル基等の酸素原子を有するＣ８～Ｃ１８のアルキル基等が挙げられる。
The “C8-C18 hydrocarbon group” of the above-mentioned “linear or branched C8-C18 hydrocarbon group optionally having an oxygen atom” includes an octyl group, an i-octyl group, and an s-octyl group. , T-octyl group, nonyl group, decyl group, undecyl group, dodecyl group, tridecyl group, tetradecyl group, pentadecyl group, hexadecyl group, heptadecyl group, octadecyl group, etc. C8-C18 alkyl group, 1-methoxyheptadecyl group And C8-C18 alkyl groups having an oxygen atom such as 1-methoxyethoxytetradecyl group and 1-methoxyethoxyethoxydodecyl group.
また、Ｘ－として、例えば、ハロゲンイオン、有機酸イオン、無機酸イオンが挙げられるが、クロルイオン、ブロムイオン等のハロゲンイオン、硫酸ジメチル、硫酸ジエチル等の有機スルホン酸イオン、ギ酸、酢酸、プロピオン酸等のカルボン酸イオンが好ましい。
Examples of X − include halogen ions, organic acid ions and inorganic acid ions. Halogen ions such as chloro ion and brom ion, organic sulfonate ions such as dimethyl sulfate and diethyl sulfate, formic acid, acetic acid and propion. Carboxylic acid ions such as acids are preferred.
一般式（Ｉ）で表される第四級アンモニウム塩系界面活性剤としては、具体的には、塩化ベンザルコニウム、塩化ベンゼトニウム、塩化ジメチルアンモニウム、塩化テトラデシルジメチルベンジルアンモニウム等を例示することができるが、塩化ベンザルコニウムが特に好ましい。
なお、塩化ベンザルコニウムは、一般式〔Ｃ６Ｈ５ＣＨ２Ｎ（ＣＨ３）２Ｒ〕＋Ｃｌ－（ここで、Ｒは、炭素数８から１８のアルキル基である。）で示される第四級アンモニウム塩である。
具体的には、オクチルジメチルベンジルアンモニウムクロライド、デシルジメチルベンジルアンモニウムクロライド、ドデシルジメチルベンジルアンモニウムクロライド、テトラデシルジメチルベンジルアンモニウムクロライド、ヘキサデシルジメチルベンジルアンモニウムクロライド、オクタデシルジメチルベンジルアンモニウムクロライド、ヤシアルキルジメチルベンジルアンモニウムクロライド等が挙げられる。好ましくは、テトラデシルジメチルベンジルアンモニウムクロライド、ヤシアルキルジメチルベンジルアンモニウムクロライドである。
本発明の抗パルボウイルス組成物中における第四級アンモニウム塩系界面活性剤の含有量は、組成物全量に対して０．００１～５０質量％、好ましくは、０．０１～１０％である。 Specific examples of the quaternary ammonium salt surfactant represented by the general formula (I) include benzalkonium chloride, benzethonium chloride, dimethylammonium chloride, and tetradecyldimethylbenzylammonium chloride. Although possible, benzalkonium chloride is particularly preferred.
Benzalkonium chloride is represented by the general formula [C 6 H 5 CH 2 N (CH 3 ) 2 R] + Cl − (wherein R is an alkyl group having 8 to 18 carbon atoms). Quaternary ammonium salt.
Specifically, octyldimethylbenzylammonium chloride, decyldimethylbenzylammonium chloride, dodecyldimethylbenzylammonium chloride, tetradecyldimethylbenzylammonium chloride, hexadecyldimethylbenzylammonium chloride, octadecyldimethylbenzylammonium chloride, cocoalkyldimethylbenzylammonium chloride, etc. Is mentioned. Tetradecyldimethylbenzylammonium chloride and cocoalkyldimethylbenzylammonium chloride are preferable.
The content of the quaternary ammonium salt surfactant in the anti-parvovirus composition of the present invention is 0.001 to 50% by mass, preferably 0.01 to 10%, based on the total amount of the composition.
なお、塩化ベンザルコニウムは、一般式〔Ｃ６Ｈ５ＣＨ２Ｎ（ＣＨ３）２Ｒ〕＋Ｃｌ－（ここで、Ｒは、炭素数８から１８のアルキル基である。）で示される第四級アンモニウム塩である。
具体的には、オクチルジメチルベンジルアンモニウムクロライド、デシルジメチルベンジルアンモニウムクロライド、ドデシルジメチルベンジルアンモニウムクロライド、テトラデシルジメチルベンジルアンモニウムクロライド、ヘキサデシルジメチルベンジルアンモニウムクロライド、オクタデシルジメチルベンジルアンモニウムクロライド、ヤシアルキルジメチルベンジルアンモニウムクロライド等が挙げられる。好ましくは、テトラデシルジメチルベンジルアンモニウムクロライド、ヤシアルキルジメチルベンジルアンモニウムクロライドである。
本発明の抗パルボウイルス組成物中における第四級アンモニウム塩系界面活性剤の含有量は、組成物全量に対して０．００１～５０質量％、好ましくは、０．０１～１０％である。 Specific examples of the quaternary ammonium salt surfactant represented by the general formula (I) include benzalkonium chloride, benzethonium chloride, dimethylammonium chloride, and tetradecyldimethylbenzylammonium chloride. Although possible, benzalkonium chloride is particularly preferred.
Benzalkonium chloride is represented by the general formula [C 6 H 5 CH 2 N (CH 3 ) 2 R] + Cl − (wherein R is an alkyl group having 8 to 18 carbon atoms). Quaternary ammonium salt.
Specifically, octyldimethylbenzylammonium chloride, decyldimethylbenzylammonium chloride, dodecyldimethylbenzylammonium chloride, tetradecyldimethylbenzylammonium chloride, hexadecyldimethylbenzylammonium chloride, octadecyldimethylbenzylammonium chloride, cocoalkyldimethylbenzylammonium chloride, etc. Is mentioned. Tetradecyldimethylbenzylammonium chloride and cocoalkyldimethylbenzylammonium chloride are preferable.
The content of the quaternary ammonium salt surfactant in the anti-parvovirus composition of the present invention is 0.001 to 50% by mass, preferably 0.01 to 10%, based on the total amount of the composition.
（キトサン、その誘導体又はそれらの塩）
キトサンは、例えば、カニ、エビ等の甲殻、昆虫類の外皮その他のキチン質源を細粉し、希塩酸で処理して炭酸カルシウムを除き、アルカリ濃溶液で処理してタンパク質その他の夾雑物を除いて得られるキチンを、高温下、高濃度アルカリにより脱アセチル化して得られる白色無定形粉末の、グルコサミンを繰り返し単位とする塩基性多糖類である。キトサンは、その分子量が数千～数十万のものであるが、殺菌効果からすると低分子量の方が望ましい。また、脱アセチル化度に関しては５０％以上、水溶性及び静菌効果を考慮すると８０％以上が好ましい。そして、遊離のキトサン自体は水に溶けないことから、無機酸又は有機酸で処理して水に可溶であるキトサン塩として用いてもよいし、また塩酸、リン酸などの無機酸や酢酸、乳酸、クエン酸、グルコン酸等の有機酸などに溶解して用いてもよい。
本発明の抗パルボウイルス組成物にキトサン、その誘導体又はそれらの塩を添加することができる。これにより第四級アンモニウム塩の抗ウイルス効果をさらに高めることができる。また、キトサンにより天然被膜を形成することができる。これにより持続的に抗ウイルス効果が発揮される。さらに簡単に水で洗浄することができる。 (Chitosan, its derivatives or their salts)
Chitosan, for example, shells of crab, shrimp, etc., insect hulls and other chitinous sources are finely ground, treated with dilute hydrochloric acid to remove calcium carbonate, and treated with an alkaline concentrated solution to remove proteins and other contaminants. It is a basic polysaccharide of white amorphous powder obtained by deacetylating chitin obtained by high-concentration alkali at a high temperature and having glucosamine as a repeating unit. Chitosan has a molecular weight of several thousands to several hundred thousand, but a lower molecular weight is desirable from the viewpoint of bactericidal effect. Further, the degree of deacetylation is preferably 50% or more and 80% or more in consideration of water solubility and bacteriostatic effect. And since free chitosan itself is not soluble in water, it may be used as a chitosan salt which is treated with an inorganic acid or an organic acid and is soluble in water, or an inorganic acid such as hydrochloric acid or phosphoric acid, acetic acid, It may be dissolved in an organic acid such as lactic acid, citric acid or gluconic acid.
Chitosan, a derivative thereof or a salt thereof can be added to the anti-parvovirus composition of the present invention. This can further enhance the antiviral effect of the quaternary ammonium salt. Moreover, a natural film can be formed with chitosan. Thereby, an antiviral effect is exhibited continuously. It can be easily washed with water.
キトサンは、例えば、カニ、エビ等の甲殻、昆虫類の外皮その他のキチン質源を細粉し、希塩酸で処理して炭酸カルシウムを除き、アルカリ濃溶液で処理してタンパク質その他の夾雑物を除いて得られるキチンを、高温下、高濃度アルカリにより脱アセチル化して得られる白色無定形粉末の、グルコサミンを繰り返し単位とする塩基性多糖類である。キトサンは、その分子量が数千～数十万のものであるが、殺菌効果からすると低分子量の方が望ましい。また、脱アセチル化度に関しては５０％以上、水溶性及び静菌効果を考慮すると８０％以上が好ましい。そして、遊離のキトサン自体は水に溶けないことから、無機酸又は有機酸で処理して水に可溶であるキトサン塩として用いてもよいし、また塩酸、リン酸などの無機酸や酢酸、乳酸、クエン酸、グルコン酸等の有機酸などに溶解して用いてもよい。
本発明の抗パルボウイルス組成物にキトサン、その誘導体又はそれらの塩を添加することができる。これにより第四級アンモニウム塩の抗ウイルス効果をさらに高めることができる。また、キトサンにより天然被膜を形成することができる。これにより持続的に抗ウイルス効果が発揮される。さらに簡単に水で洗浄することができる。 (Chitosan, its derivatives or their salts)
Chitosan, for example, shells of crab, shrimp, etc., insect hulls and other chitinous sources are finely ground, treated with dilute hydrochloric acid to remove calcium carbonate, and treated with an alkaline concentrated solution to remove proteins and other contaminants. It is a basic polysaccharide of white amorphous powder obtained by deacetylating chitin obtained by high-concentration alkali at a high temperature and having glucosamine as a repeating unit. Chitosan has a molecular weight of several thousands to several hundred thousand, but a lower molecular weight is desirable from the viewpoint of bactericidal effect. Further, the degree of deacetylation is preferably 50% or more and 80% or more in consideration of water solubility and bacteriostatic effect. And since free chitosan itself is not soluble in water, it may be used as a chitosan salt which is treated with an inorganic acid or an organic acid and is soluble in water, or an inorganic acid such as hydrochloric acid or phosphoric acid, acetic acid, It may be dissolved in an organic acid such as lactic acid, citric acid or gluconic acid.
Chitosan, a derivative thereof or a salt thereof can be added to the anti-parvovirus composition of the present invention. This can further enhance the antiviral effect of the quaternary ammonium salt. Moreover, a natural film can be formed with chitosan. Thereby, an antiviral effect is exhibited continuously. It can be easily washed with water.
本発明に用いられるキトサン誘導体としては、キトサンの遊離のアミノ基又は水酸基をすべてあるいは部分的にアルキル基（好ましくはＣ１～Ｃ６アルキル基）、アルコキシアルキル基（好ましくはＣ１～Ｃ６アルコキシＣ１～Ｃ６アルキル基）、アルキルチオアルキル基（好ましくはＣ１～Ｃ６アルキルチオＣ１～Ｃ６アルキル基）、アリール基（好ましくはＣ６～Ｃ１０アリール基）、アラルキル基（好ましくはＣ６～Ｃ１０アリールＣ１～Ｃ６アルキル基）、アシル基（好ましくはＣ１～Ｃ６アシル基）、スルホニル基、アルコキシカルボニル基（好ましくはＣ１～Ｃ６アルコキシカルボニル基）又はリン酸残基等により化学修飾されたものを挙げることができる。
本発明の抗パルボウイルス組成物中におけるキトサン、その誘導体又はそれら塩の含有量は、組成物全量に対して０．０１～５０質量％、好ましくは、０．０５～１０質量％である。また、好ましくは脱アセチル化度は８０％以上、２０℃における１質量％酢酸溶液の粘度は、０．１～５０ｍＰａ・ｓである。 The chitosan derivative used in the present invention includes all or part of the free amino group or hydroxyl group of chitosan, preferably an alkyl group (preferably a C1-C6 alkyl group), an alkoxyalkyl group (preferably a C1-C6 alkoxy C1-C6 alkyl). Group), alkylthioalkyl group (preferably C1-C6 alkylthio C1-C6 alkyl group), aryl group (preferably C6-C10 aryl group), aralkyl group (preferably C6-C10 aryl C1-C6 alkyl group), acyl group (Preferably a C1 to C6 acyl group), a sulfonyl group, an alkoxycarbonyl group (preferably a C1 to C6 alkoxycarbonyl group), a phosphoric acid residue or the like may be mentioned.
The content of chitosan, a derivative thereof or a salt thereof in the anti-parvovirus composition of the present invention is 0.01 to 50% by mass, preferably 0.05 to 10% by mass with respect to the total amount of the composition. The degree of deacetylation is preferably 80% or more, and the viscosity of a 1% by mass acetic acid solution at 20 ° C. is 0.1 to 50 mPa · s.
本発明の抗パルボウイルス組成物中におけるキトサン、その誘導体又はそれら塩の含有量は、組成物全量に対して０．０１～５０質量％、好ましくは、０．０５～１０質量％である。また、好ましくは脱アセチル化度は８０％以上、２０℃における１質量％酢酸溶液の粘度は、０．１～５０ｍＰａ・ｓである。 The chitosan derivative used in the present invention includes all or part of the free amino group or hydroxyl group of chitosan, preferably an alkyl group (preferably a C1-C6 alkyl group), an alkoxyalkyl group (preferably a C1-C6 alkoxy C1-C6 alkyl). Group), alkylthioalkyl group (preferably C1-C6 alkylthio C1-C6 alkyl group), aryl group (preferably C6-C10 aryl group), aralkyl group (preferably C6-C10 aryl C1-C6 alkyl group), acyl group (Preferably a C1 to C6 acyl group), a sulfonyl group, an alkoxycarbonyl group (preferably a C1 to C6 alkoxycarbonyl group), a phosphoric acid residue or the like may be mentioned.
The content of chitosan, a derivative thereof or a salt thereof in the anti-parvovirus composition of the present invention is 0.01 to 50% by mass, preferably 0.05 to 10% by mass with respect to the total amount of the composition. The degree of deacetylation is preferably 80% or more, and the viscosity of a 1% by mass acetic acid solution at 20 ° C. is 0.1 to 50 mPa · s.
これらのキトサン誘導体は、例えば以下の文献記載の手法等、通常の有機合成化学的な化学修飾によって得ることが出来る。
（１）公開特許公報 昭５７－１８０６０２号
（２）公開特許公報 昭５９－１０６４０９号 These chitosan derivatives can be obtained, for example, by ordinary organic synthetic chemical modification such as the method described in the following literature.
(1) Published Patent Publication No. 57-180602 (2) Published Patent Publication No. 59-106409
（１）公開特許公報 昭５７－１８０６０２号
（２）公開特許公報 昭５９－１０６４０９号 These chitosan derivatives can be obtained, for example, by ordinary organic synthetic chemical modification such as the method described in the following literature.
(1) Published Patent Publication No. 57-180602 (2) Published Patent Publication No. 59-106409
（保湿剤）
保湿剤とは、湿度を保つ働きのある成分を示し、例えば、グリセリン等を例示することができる。
（ｐＨ調整剤）
ｐＨ調整剤とは、溶液のｐＨを適正な値にするために添加するものであり、例えば、酢酸、乳酸、クエン酸等のカルボン酸等を例示することができる。
ｐＨは３～６が好ましい。
（アクリジン及びアクリジン誘導体）
アクリジン誘導体はアクリジン骨格を有する化合物を表す。また、アクリジンは発ガン性物質の可能性があることが知られている。そのため、本発明においては含有しない。 (Humectant)
A humectant shows the component which has a function which maintains humidity, for example, glycerol etc. can be illustrated.
(PH adjuster)
The pH adjuster is added to adjust the pH of the solution to an appropriate value, and examples thereof include carboxylic acids such as acetic acid, lactic acid, and citric acid.
The pH is preferably 3-6.
(Acridine and acridine derivatives)
The acridine derivative represents a compound having an acridine skeleton. Acridine is also known to be a carcinogenic substance. Therefore, it does not contain in this invention.
保湿剤とは、湿度を保つ働きのある成分を示し、例えば、グリセリン等を例示することができる。
（ｐＨ調整剤）
ｐＨ調整剤とは、溶液のｐＨを適正な値にするために添加するものであり、例えば、酢酸、乳酸、クエン酸等のカルボン酸等を例示することができる。
ｐＨは３～６が好ましい。
（アクリジン及びアクリジン誘導体）
アクリジン誘導体はアクリジン骨格を有する化合物を表す。また、アクリジンは発ガン性物質の可能性があることが知られている。そのため、本発明においては含有しない。 (Humectant)
A humectant shows the component which has a function which maintains humidity, for example, glycerol etc. can be illustrated.
(PH adjuster)
The pH adjuster is added to adjust the pH of the solution to an appropriate value, and examples thereof include carboxylic acids such as acetic acid, lactic acid, and citric acid.
The pH is preferably 3-6.
(Acridine and acridine derivatives)
The acridine derivative represents a compound having an acridine skeleton. Acridine is also known to be a carcinogenic substance. Therefore, it does not contain in this invention.
（抗パルボウイルス組成物の調製）
本発明の抗パルボウイルス組成物の調製法は、特に制限はないが、例えば、まず全成分の適切な量を水等の溶媒に溶かし、必要に応じてｐＨ調節剤を添加してｐＨを調整し、水を最終重量となるまで添加する。組成物をさらに滅菌して適切な容器内に保存することもできる。 (Preparation of anti-parvovirus composition)
The method for preparing the anti-parvovirus composition of the present invention is not particularly limited. For example, first, an appropriate amount of all components is dissolved in a solvent such as water, and a pH adjuster is added as necessary to adjust the pH. And add water to final weight. The composition can be further sterilized and stored in a suitable container.
本発明の抗パルボウイルス組成物の調製法は、特に制限はないが、例えば、まず全成分の適切な量を水等の溶媒に溶かし、必要に応じてｐＨ調節剤を添加してｐＨを調整し、水を最終重量となるまで添加する。組成物をさらに滅菌して適切な容器内に保存することもできる。 (Preparation of anti-parvovirus composition)
The method for preparing the anti-parvovirus composition of the present invention is not particularly limited. For example, first, an appropriate amount of all components is dissolved in a solvent such as water, and a pH adjuster is added as necessary to adjust the pH. And add water to final weight. The composition can be further sterilized and stored in a suitable container.
（抗パルボウイルス組成物の使用法）
本発明の抗パルボウイルス組成物は、ヒト、動物に対して溶液、ゲル、懸濁液、ローション、軟膏、クリーム、テープ等の形状でヒト、動物や、器物、ペット用品等に塗布、貼付等することができる。また、本発明の抗パルボウイルス組成物は、紙、ガーゼ、脱脂綿又は不織布等の繊維素材からなる担体、例えば、おしぼり、ぞうきん、布巾、抗菌膜、ティッシュペーパー、ウエットティッシュ（登録商標）、ウエットワイパー（登録商標）等に含浸させてヒト、動物、器物等を拭くことができる。また、アルコール等の有機溶媒と共に噴霧容器に入れて噴霧してもよい。
本発明の抗パルボウイルス組成物の具体的な使用態様としては、本発明の抗パルボウイルス組成物を含有するペット用殺菌抗ウイルス剤、繊維素材、クリーム剤、抗菌抗ウイルス膜等が挙げられる。 (Usage of anti-parvovirus composition)
The anti-parvovirus composition of the present invention is applied to humans, animals, containers, pet supplies, etc. in the form of solutions, gels, suspensions, lotions, ointments, creams, tapes, etc. for humans and animals. can do. In addition, the anti-parvovirus composition of the present invention is a carrier made of a fiber material such as paper, gauze, absorbent cotton, or non-woven fabric, such as a towel, a rag, a cloth, an antibacterial film, a tissue paper, a wet tissue (registered trademark), a wet wiper. (Registered Trademark) or the like can be impregnated to wipe humans, animals, instruments and the like. Moreover, you may spray in a spray container with organic solvents, such as alcohol.
Specific uses of the anti-parvovirus composition of the present invention include pet antibacterial antiviral agents, fiber materials, creams, antibacterial antiviral membranes and the like containing the anti-parvovirus composition of the present invention.
本発明の抗パルボウイルス組成物は、ヒト、動物に対して溶液、ゲル、懸濁液、ローション、軟膏、クリーム、テープ等の形状でヒト、動物や、器物、ペット用品等に塗布、貼付等することができる。また、本発明の抗パルボウイルス組成物は、紙、ガーゼ、脱脂綿又は不織布等の繊維素材からなる担体、例えば、おしぼり、ぞうきん、布巾、抗菌膜、ティッシュペーパー、ウエットティッシュ（登録商標）、ウエットワイパー（登録商標）等に含浸させてヒト、動物、器物等を拭くことができる。また、アルコール等の有機溶媒と共に噴霧容器に入れて噴霧してもよい。
本発明の抗パルボウイルス組成物の具体的な使用態様としては、本発明の抗パルボウイルス組成物を含有するペット用殺菌抗ウイルス剤、繊維素材、クリーム剤、抗菌抗ウイルス膜等が挙げられる。 (Usage of anti-parvovirus composition)
The anti-parvovirus composition of the present invention is applied to humans, animals, containers, pet supplies, etc. in the form of solutions, gels, suspensions, lotions, ointments, creams, tapes, etc. for humans and animals. can do. In addition, the anti-parvovirus composition of the present invention is a carrier made of a fiber material such as paper, gauze, absorbent cotton, or non-woven fabric, such as a towel, a rag, a cloth, an antibacterial film, a tissue paper, a wet tissue (registered trademark), a wet wiper. (Registered Trademark) or the like can be impregnated to wipe humans, animals, instruments and the like. Moreover, you may spray in a spray container with organic solvents, such as alcohol.
Specific uses of the anti-parvovirus composition of the present invention include pet antibacterial antiviral agents, fiber materials, creams, antibacterial antiviral membranes and the like containing the anti-parvovirus composition of the present invention.
（ペット用殺菌抗ウイルス剤）
ペット用の器具等に細菌等の菌が繁殖し、そして、ペットの口から菌が取り込まれるとペットが内臓疾患になり、皮膚に菌が付着すると皮膚炎等の疾患になることが予想される。また、疾患に至らなくても、ペット匂いの原因として細菌が関っている。そのため、ペット用殺菌剤をペット用器具などに塗布、噴霧する。そのペット用殺菌剤に本発明の抗パルボウイルス組成物を含有させることができる。
しかし、薬効の殺菌剤や除菌剤、抗菌剤はペットに対して刺激や匂いが強く使用することができない。さらに菌に対して効果があっても、ウイルスに効果があるとは限らない。
本発明の抗パルボウイルス組成物は、パルボウイルスを不活性化するだけではなく、様々な細菌に対しても殺菌効果があるため、それ自体をペット用の器具の殺菌剤として使用することができる。さらに、刺激性も匂いもなく、ペットに対して安心して使用することができる。
なお殺菌とは、菌を殺す効力があることを示すものである。 (Bactericidal antiviral agent for pets)
Bacteria such as bacteria propagate in pet equipment, etc., and if bacteria are taken from the pet's mouth, the pet will become visceral disease, and if bacteria adhere to the skin, it is expected to become a disease such as dermatitis . Moreover, even if it does not lead to a disease, bacteria are involved as a cause of pet odor. Therefore, a pet bactericidal agent is applied and sprayed on a pet instrument. The pet disinfectant can contain the anti-parvovirus composition of the present invention.
However, medicinal bactericides, disinfectants, and antibacterial agents cannot be used because they have strong irritation and smell to pets. Furthermore, even if it is effective against bacteria, it is not always effective against viruses.
Since the anti-parvovirus composition of the present invention not only inactivates parvovirus but also has a bactericidal effect against various bacteria, it can be used as a bactericidal agent for pet equipment. . Furthermore, there is no irritation and no smell, and it can be used with confidence for pets.
Sterilization means that it has the effect of killing bacteria.
ペット用の器具等に細菌等の菌が繁殖し、そして、ペットの口から菌が取り込まれるとペットが内臓疾患になり、皮膚に菌が付着すると皮膚炎等の疾患になることが予想される。また、疾患に至らなくても、ペット匂いの原因として細菌が関っている。そのため、ペット用殺菌剤をペット用器具などに塗布、噴霧する。そのペット用殺菌剤に本発明の抗パルボウイルス組成物を含有させることができる。
しかし、薬効の殺菌剤や除菌剤、抗菌剤はペットに対して刺激や匂いが強く使用することができない。さらに菌に対して効果があっても、ウイルスに効果があるとは限らない。
本発明の抗パルボウイルス組成物は、パルボウイルスを不活性化するだけではなく、様々な細菌に対しても殺菌効果があるため、それ自体をペット用の器具の殺菌剤として使用することができる。さらに、刺激性も匂いもなく、ペットに対して安心して使用することができる。
なお殺菌とは、菌を殺す効力があることを示すものである。 (Bactericidal antiviral agent for pets)
Bacteria such as bacteria propagate in pet equipment, etc., and if bacteria are taken from the pet's mouth, the pet will become visceral disease, and if bacteria adhere to the skin, it is expected to become a disease such as dermatitis . Moreover, even if it does not lead to a disease, bacteria are involved as a cause of pet odor. Therefore, a pet bactericidal agent is applied and sprayed on a pet instrument. The pet disinfectant can contain the anti-parvovirus composition of the present invention.
However, medicinal bactericides, disinfectants, and antibacterial agents cannot be used because they have strong irritation and smell to pets. Furthermore, even if it is effective against bacteria, it is not always effective against viruses.
Since the anti-parvovirus composition of the present invention not only inactivates parvovirus but also has a bactericidal effect against various bacteria, it can be used as a bactericidal agent for pet equipment. . Furthermore, there is no irritation and no smell, and it can be used with confidence for pets.
Sterilization means that it has the effect of killing bacteria.
（繊維素材）
本発明の抗パルボウイルス組成物を含有させた繊維素材は、ペット用の器具を拭くことで含有させた薬剤が器具に付着し、抗ウイルス性によってその器具に付着したウイルスを不活性化することができる。また、拭き取る操作により器具に付着した細菌、ウイルス等を繊維素材にからめとることができる。繊維素材中に残っている抗パルボウイルス組成物によって、殺菌またはウイルスの不活性化が起こるため、他の部位を拭く時に細菌やウイルスを拡散させることが無い。
また、予めバケツ等の容器に本発明の抗パルボウイルス組成物の溶液を入れ、ぞうきん等を浸して絞った後にペットを拭くことで、ペットの体毛に付着した細菌やウイルスを除去でき、さらにペットの体臭を低減することができる。 (Fiber material)
In the fiber material containing the anti-parvovirus composition of the present invention, the medicine contained by wiping the pet equipment adheres to the equipment, and the virus attached to the equipment is inactivated by antiviral properties. Can do. In addition, bacteria, viruses and the like attached to the instrument can be entangled in the fiber material by the wiping operation. The anti-parvovirus composition remaining in the fiber material causes sterilization or virus inactivation, so that bacteria and viruses are not diffused when wiping other parts.
In addition, bacteria and viruses attached to the pet's body hair can be removed by placing the anti-parvovirus composition solution of the present invention in a bucket or the like in advance, immersing and squeezing elephant, etc., and wiping the pet. The body odor can be reduced.
本発明の抗パルボウイルス組成物を含有させた繊維素材は、ペット用の器具を拭くことで含有させた薬剤が器具に付着し、抗ウイルス性によってその器具に付着したウイルスを不活性化することができる。また、拭き取る操作により器具に付着した細菌、ウイルス等を繊維素材にからめとることができる。繊維素材中に残っている抗パルボウイルス組成物によって、殺菌またはウイルスの不活性化が起こるため、他の部位を拭く時に細菌やウイルスを拡散させることが無い。
また、予めバケツ等の容器に本発明の抗パルボウイルス組成物の溶液を入れ、ぞうきん等を浸して絞った後にペットを拭くことで、ペットの体毛に付着した細菌やウイルスを除去でき、さらにペットの体臭を低減することができる。 (Fiber material)
In the fiber material containing the anti-parvovirus composition of the present invention, the medicine contained by wiping the pet equipment adheres to the equipment, and the virus attached to the equipment is inactivated by antiviral properties. Can do. In addition, bacteria, viruses and the like attached to the instrument can be entangled in the fiber material by the wiping operation. The anti-parvovirus composition remaining in the fiber material causes sterilization or virus inactivation, so that bacteria and viruses are not diffused when wiping other parts.
In addition, bacteria and viruses attached to the pet's body hair can be removed by placing the anti-parvovirus composition solution of the present invention in a bucket or the like in advance, immersing and squeezing elephant, etc., and wiping the pet. The body odor can be reduced.
（クリーム剤）
本発明の抗パルボウイルス成分に水、各種油、アルコール、界面活性剤、防腐剤等を加えた後、攪拌することでクリーム状の抗パルボウイルス成分を含有するクリーム剤を製造することができる。
このクリーム剤は、直接ペットの皮膚に塗布することができる。これによりペットの硬い皮膚を軟化させ、抗パルボウイルス成分が皮膚に浸透しやすくする効果がある。例えばペットの肉球に発生した傷にこのクリーム剤を塗布することで、細菌等による皮膚炎を防止でき、傷からパルボウイルスの進入を抑えることができる。さらにクリーム剤の効果で長く皮膚に抗パルボウイルス剤が留まることで、長い期間抗パルボウイルス性が持続する。 (Cream)
After adding water, various oils, alcohol, surfactant, preservative, etc. to the anti-parvovirus component of this invention, the cream agent containing a cream-like anti-parvovirus component can be manufactured by stirring.
This cream can be applied directly to the skin of a pet. This has the effect of softening the hard skin of the pet and facilitating penetration of the anti-parvovirus component into the skin. For example, by applying this cream to a wound generated on a pet's paws, dermatitis due to bacteria or the like can be prevented, and entry of parvovirus from the wound can be suppressed. Furthermore, the anti-parvovirus agent persists for a long period of time due to the effect of the cream so that the anti-parvovirus agent remains on the skin for a long time.
本発明の抗パルボウイルス成分に水、各種油、アルコール、界面活性剤、防腐剤等を加えた後、攪拌することでクリーム状の抗パルボウイルス成分を含有するクリーム剤を製造することができる。
このクリーム剤は、直接ペットの皮膚に塗布することができる。これによりペットの硬い皮膚を軟化させ、抗パルボウイルス成分が皮膚に浸透しやすくする効果がある。例えばペットの肉球に発生した傷にこのクリーム剤を塗布することで、細菌等による皮膚炎を防止でき、傷からパルボウイルスの進入を抑えることができる。さらにクリーム剤の効果で長く皮膚に抗パルボウイルス剤が留まることで、長い期間抗パルボウイルス性が持続する。 (Cream)
After adding water, various oils, alcohol, surfactant, preservative, etc. to the anti-parvovirus component of this invention, the cream agent containing a cream-like anti-parvovirus component can be manufactured by stirring.
This cream can be applied directly to the skin of a pet. This has the effect of softening the hard skin of the pet and facilitating penetration of the anti-parvovirus component into the skin. For example, by applying this cream to a wound generated on a pet's paws, dermatitis due to bacteria or the like can be prevented, and entry of parvovirus from the wound can be suppressed. Furthermore, the anti-parvovirus agent persists for a long period of time due to the effect of the cream so that the anti-parvovirus agent remains on the skin for a long time.
（抗菌抗ウイルス膜）
本発明の抗パルボウイルス組成物に、さらにキトサン又はその塩、又はキトサン誘導体又はその塩、を加えることで、塗布後、抗菌抗ウイルス膜を作成することができる。この抗菌抗ウイルス膜は、抗パルボウイルス成分を含有しているので細菌やパルボウイルスを不活性化し、さらにその状態を長く維持することができる。
なお、抗菌とは微生物の発生、成育、増殖を抑制することを示すものである。 (Antimicrobial antiviral membrane)
By adding chitosan or a salt thereof, or a chitosan derivative or a salt thereof to the anti-parvovirus composition of the present invention, an antibacterial antiviral film can be prepared after application. Since this antibacterial antiviral film contains an anti-parvovirus component, it can inactivate bacteria and parvovirus and can maintain the state for a long time.
Antibacterial means to suppress the generation, growth and proliferation of microorganisms.
本発明の抗パルボウイルス組成物に、さらにキトサン又はその塩、又はキトサン誘導体又はその塩、を加えることで、塗布後、抗菌抗ウイルス膜を作成することができる。この抗菌抗ウイルス膜は、抗パルボウイルス成分を含有しているので細菌やパルボウイルスを不活性化し、さらにその状態を長く維持することができる。
なお、抗菌とは微生物の発生、成育、増殖を抑制することを示すものである。 (Antimicrobial antiviral membrane)
By adding chitosan or a salt thereof, or a chitosan derivative or a salt thereof to the anti-parvovirus composition of the present invention, an antibacterial antiviral film can be prepared after application. Since this antibacterial antiviral film contains an anti-parvovirus component, it can inactivate bacteria and parvovirus and can maintain the state for a long time.
Antibacterial means to suppress the generation, growth and proliferation of microorganisms.
以下実施例を用いて本発明を詳細に説明するが、本発明の技術的範囲はこれらの例示に限定されるものではない。なお、ＧＩＢＣＯは登録商標名である。
塩化ベンザルコニウムは、日油株式会社製テトラデシルジメチルベンジルアンモニウムクロライドを使用し、キトサンは粘度１０ｍＰａ・ｓ（１質量％酢酸溶液、２０℃）、脱アセチル化度９０％のものを使用したが、本発明はこれらの原料に限定されなくても良い。 EXAMPLES Hereinafter, although this invention is demonstrated in detail using an Example, the technical scope of this invention is not limited to these illustrations. GIBCO is a registered trademark name.
Benzalkonium chloride uses tetradecyldimethylbenzylammonium chloride manufactured by NOF Corporation, and chitosan has a viscosity of 10 mPa · s (1% by mass acetic acid solution, 20 ° C.) and a deacetylation degree of 90%. The present invention need not be limited to these raw materials.
塩化ベンザルコニウムは、日油株式会社製テトラデシルジメチルベンジルアンモニウムクロライドを使用し、キトサンは粘度１０ｍＰａ・ｓ（１質量％酢酸溶液、２０℃）、脱アセチル化度９０％のものを使用したが、本発明はこれらの原料に限定されなくても良い。 EXAMPLES Hereinafter, although this invention is demonstrated in detail using an Example, the technical scope of this invention is not limited to these illustrations. GIBCO is a registered trademark name.
Benzalkonium chloride uses tetradecyldimethylbenzylammonium chloride manufactured by NOF Corporation, and chitosan has a viscosity of 10 mPa · s (1% by mass acetic acid solution, 20 ° C.) and a deacetylation degree of 90%. The present invention need not be limited to these raw materials.
１ 抗パルボウイルス剤の調製
［実施例１～４、比較例１～４］
第１表の組成になるように各成分をガラス容器に入れて、室温で数時間、攪拌混合し、実施例１～４及び比較例１～４の各試料を作製した。 1. Preparation of anti-parvovirus agent
[Examples 1 to 4, Comparative Examples 1 to 4]
Each component was put in a glass container so as to have the composition shown in Table 1, and stirred and mixed at room temperature for several hours to prepare samples of Examples 1 to 4 and Comparative Examples 1 to 4.
［実施例１～４、比較例１～４］
第１表の組成になるように各成分をガラス容器に入れて、室温で数時間、攪拌混合し、実施例１～４及び比較例１～４の各試料を作製した。 1. Preparation of anti-parvovirus agent
[Examples 1 to 4, Comparative Examples 1 to 4]
Each component was put in a glass container so as to have the composition shown in Table 1, and stirred and mixed at room temperature for several hours to prepare samples of Examples 1 to 4 and Comparative Examples 1 to 4.
（ウイルスの調製）
イヌパルボウイルスＫＭＣ９１１２１２株（ＣＰＶ）をＭＤＣＫ細胞(イヌ腎細胞;ＲＣＢ０９９５株)に感染させ、３７℃、５％ＣＯ２存在下で７２時間培養した。連続して５代継代したものを大量培養した。尚、ウイルス液の一部は、１０倍階段希釈法にて細胞変性効果を確認し、ウイルス感染力価(ＴＣＩＤ５０)を測定した。
Canine parvovirus KMC91112 strain (CPV) was infected with MDCK cells (canine kidney cells; RCB0995 strain) and cultured at 37 ° C. in the presence of 5% CO 2 for 72 hours. Mass culture was performed after 5 consecutive passages. A part of the virus solution was confirmed for cytopathic effect by a 10-fold serial dilution method, and the virus infectivity titer (TCID 50 ) was measured.
（ウイルス感染力価（ＴＣＩＤ５０）の測定）
前記実施例１～４及び比較例１～４それぞれ２ｍＬずつと、調製したＣＰＶ液２ｍＬとを混合し、所定の時間、感作させた。感作時間は、１分、５分、１０分及び２０分とし、それぞれの感作時間終了後、１０倍階段希釈を施した。予備試験の結果より、測定試料の最小希釈倍数は１／１００倍とし、１／１０００倍希釈液よりウイルス感染力価判定に使用した。 (Measurement of virus infectivity titer (TCID50))
2 mL each of Examples 1 to 4 and Comparative Examples 1 to 4 and 2 mL of the prepared CPV solution were mixed and sensitized for a predetermined time. The sensitization time was 1 minute, 5 minutes, 10 minutes, and 20 minutes, and after each sensitization time, 10-fold serial dilution was performed. From the result of the preliminary test, the minimum dilution factor of the measurement sample was 1/100 times, and the virus infection titer was determined from the 1/1000 times dilution.
前記実施例１～４及び比較例１～４それぞれ２ｍＬずつと、調製したＣＰＶ液２ｍＬとを混合し、所定の時間、感作させた。感作時間は、１分、５分、１０分及び２０分とし、それぞれの感作時間終了後、１０倍階段希釈を施した。予備試験の結果より、測定試料の最小希釈倍数は１／１００倍とし、１／１０００倍希釈液よりウイルス感染力価判定に使用した。 (Measurement of virus infectivity titer (TCID50))
2 mL each of Examples 1 to 4 and Comparative Examples 1 to 4 and 2 mL of the prepared CPV solution were mixed and sensitized for a predetermined time. The sensitization time was 1 minute, 5 minutes, 10 minutes, and 20 minutes, and after each sensitization time, 10-fold serial dilution was performed. From the result of the preliminary test, the minimum dilution factor of the measurement sample was 1/100 times, and the virus infection titer was determined from the 1/1000 times dilution.
測定試料を１０倍階段希釈し、ＭＤＣＫ細胞に１００μＬ接種し、１時間接触感染させた。測定試料除去後、ウイルス維持培地１％ＢＳＡ含有イーグルＭＥＭ（ＧＩＢＣＯ）０．１ｍＬを加えて３７℃、５％ＣＯ２存在下で９６時間培養した。２４時間毎に細胞変性効果あるいは代謝阻害を観察し、ウイルス感染力価(ＴＣＩＤ５０)を測定した。
また、ＭＤＣＫ播種時の１／１０００希釈時におけるウイルス感染力価を用いて、下記式でウイルス抑制率を算出した。
例えば、実施例１の１０分後では、
となる。
感作時間１０分及び２０分におけるＴＣＩＤ５０の対数（単位：ｌｏｇＴＣＩＤ５０／ｍＬ ）を第２表に、及びウイルス抑制率（単位：％）を第３表に表す。 The measurement sample was serially diluted 10-fold, 100 μL of MDCK cells were inoculated, and contact-infected for 1 hour. After removing the measurement sample, 0.1 mL of virus maintenance medium 1% BSA-containing Eagle MEM (GIBCO) was added, and the mixture was cultured at 37 ° C. in the presence of 5% CO 2 for 96 hours. The cytopathic effect or metabolic inhibition was observed every 24 hours, and the virus infection titer (TCID50) was measured.
Moreover, the virus suppression rate was computed by the following formula using the virus infection titer at the time of 1/1000 dilution at the time of MDCK seeding.
For example, 10 minutes after Example 1,
It becomes.
The logarithm of TCID50 (unit: log TCID50 / mL) at the sensitization time of 10 minutes and 20 minutes is shown in Table 2, and the virus suppression rate (unit:%) is shown in Table 3.
また、ＭＤＣＫ播種時の１／１０００希釈時におけるウイルス感染力価を用いて、下記式でウイルス抑制率を算出した。
例えば、実施例１の１０分後では、
感作時間１０分及び２０分におけるＴＣＩＤ５０の対数（単位：ｌｏｇＴＣＩＤ５０／ｍＬ ）を第２表に、及びウイルス抑制率（単位：％）を第３表に表す。 The measurement sample was serially diluted 10-fold, 100 μL of MDCK cells were inoculated, and contact-infected for 1 hour. After removing the measurement sample, 0.1 mL of virus maintenance medium 1% BSA-containing Eagle MEM (GIBCO) was added, and the mixture was cultured at 37 ° C. in the presence of 5% CO 2 for 96 hours. The cytopathic effect or metabolic inhibition was observed every 24 hours, and the virus infection titer (TCID50) was measured.
Moreover, the virus suppression rate was computed by the following formula using the virus infection titer at the time of 1/1000 dilution at the time of MDCK seeding.
For example, 10 minutes after Example 1,
The logarithm of TCID50 (unit: log TCID50 / mL) at the sensitization time of 10 minutes and 20 minutes is shown in Table 2, and the virus suppression rate (unit:%) is shown in Table 3.
３．まとめ
実施例１の結果から、エタノールと酢酸を含有する組成物にパルボウイルスに対する不活性化の効果があることが判明した。
実施例２の結果から、さらにグリセリンを加えることでその効果が増加した。
実施例３および４の結果から、さらに塩化ベンザルコニウムやキトサンを添加しても、その効果を維持していた。 3. Summary From the results of Example 1, it was found that the composition containing ethanol and acetic acid has an inactivating effect on parvovirus.
From the result of Example 2, the effect increased by adding glycerin further.
From the results of Examples 3 and 4, even when benzalkonium chloride or chitosan was further added, the effect was maintained.
実施例１の結果から、エタノールと酢酸を含有する組成物にパルボウイルスに対する不活性化の効果があることが判明した。
実施例２の結果から、さらにグリセリンを加えることでその効果が増加した。
実施例３および４の結果から、さらに塩化ベンザルコニウムやキトサンを添加しても、その効果を維持していた。 3. Summary From the results of Example 1, it was found that the composition containing ethanol and acetic acid has an inactivating effect on parvovirus.
From the result of Example 2, the effect increased by adding glycerin further.
From the results of Examples 3 and 4, even when benzalkonium chloride or chitosan was further added, the effect was maintained.
Claims (9)
- 組成物全量に対して０．１～２０質量％のＣ１～Ｃ６アルコールと０．０１～１０質量％のＣ１～Ｃ６カルボン酸を含有することを特徴とする抗パルボウイルス組成物。 An anti-parvovirus composition comprising 0.1 to 20% by mass of a C1 to C6 alcohol and 0.01 to 10% by mass of a C1 to C6 carboxylic acid based on the total amount of the composition.
- 前記Ｃ１～Ｃ６アルコールがエタノールであることを特徴とする請求項１に記載の抗パルボウイルス組成物。 The anti-parvovirus composition according to claim 1, wherein the C1-C6 alcohol is ethanol.
- 前記Ｃ１～Ｃ６カルボン酸が酢酸であることを特徴とする請求項１又は２に記載の抗パルボウイルス組成物。 3. The anti-parvovirus composition according to claim 1, wherein the C1-C6 carboxylic acid is acetic acid.
- さらにキトサン、その誘導体又はそれらの塩を含有することを特徴とする請求項１～３のいずれかに記載の抗パルボウイルス組成物。 The anti-parvovirus composition according to any one of claims 1 to 3, further comprising chitosan, a derivative thereof or a salt thereof.
- さらに第四級アンモニウム塩系界面活性剤を含有することを特徴とする請求項１～４のいずれかに記載の抗パルボウイルス組成物。 The anti-parvovirus composition according to any one of claims 1 to 4, further comprising a quaternary ammonium salt surfactant.
- 請求項１～５のいずれかに記載の抗パルボウイルス性組成物を含有することを特徴とするペット用殺菌抗ウイルス剤。 A pet bactericidal antiviral agent comprising the anti-parvoviral composition according to any one of claims 1 to 5.
- 請求項１～５のいずれかに記載の抗パルボウイルス性組成物を含有することを特徴とする繊維素材。 A fiber material comprising the anti-parvovirus composition according to any one of claims 1 to 5.
- 請求項１～５のいずれかに記載の抗パルボウイルス性組成物を含有することを特徴とするクリーム剤。 A cream comprising the anti-parvoviral composition according to any one of claims 1 to 5.
- 請求項１～５のいずれかに記載の抗パルボウイルス性組成物を含有することを特徴とする抗菌抗ウイルス膜。 An antibacterial antiviral film comprising the antiparvoviral composition according to any one of claims 1 to 5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015547630A JP6125660B2 (en) | 2013-11-14 | 2014-11-10 | Anti-parvovirus composition |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013235799 | 2013-11-14 | ||
| JP2013-235799 | 2013-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2015072125A1 true WO2015072125A1 (en) | 2015-05-21 |
Family
ID=53057075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2014/005626 WO2015072125A1 (en) | 2013-11-14 | 2014-11-10 | Anti-parvovirus composition |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP6125660B2 (en) |
| WO (1) | WO2015072125A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017019009A1 (en) | 2015-07-27 | 2017-02-02 | Kimberly-Clark Worldwide, Inc. | Residual disinfectant composition |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0656675A (en) * | 1992-08-07 | 1994-03-01 | Nippon Soda Co Ltd | Livestock mammary inflammation-preventing agent |
| JPH111700A (en) * | 1997-06-13 | 1999-01-06 | Nippon Soda Co Ltd | Drug composition for toilet seat cleaner |
| JP2007513959A (en) * | 2003-12-10 | 2007-05-31 | エスディー ファーマシューティカルズ インコーポレイティッド | Antiviral pharmaceutical composition |
| JP2008503637A (en) * | 2004-06-25 | 2008-02-07 | エビオックス・リミテッド | Cleaning composition |
| JP2009526060A (en) * | 2006-02-09 | 2009-07-16 | ゴジョ・インダストリーズ・インコーポレイテッド | Antiviral method |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010067869A1 (en) * | 2008-12-12 | 2010-06-17 | 国立大学法人広島大学 | Anti-viral agent and anti-viral composition |
-
2014
- 2014-11-10 WO PCT/JP2014/005626 patent/WO2015072125A1/en active Application Filing
- 2014-11-10 JP JP2015547630A patent/JP6125660B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0656675A (en) * | 1992-08-07 | 1994-03-01 | Nippon Soda Co Ltd | Livestock mammary inflammation-preventing agent |
| JPH111700A (en) * | 1997-06-13 | 1999-01-06 | Nippon Soda Co Ltd | Drug composition for toilet seat cleaner |
| JP2007513959A (en) * | 2003-12-10 | 2007-05-31 | エスディー ファーマシューティカルズ インコーポレイティッド | Antiviral pharmaceutical composition |
| JP2008503637A (en) * | 2004-06-25 | 2008-02-07 | エビオックス・リミテッド | Cleaning composition |
| JP2009526060A (en) * | 2006-02-09 | 2009-07-16 | ゴジョ・インダストリーズ・インコーポレイテッド | Antiviral method |
Non-Patent Citations (2)
| Title |
|---|
| PRUSS, A. ET AL.: "Virus Safety of Avital Bone Tissue Transplants: Evaluation of Sterilization Steps of Spongiosa Cuboids Using a Peracetic Acid-Methanol Mixture", BIOLOGICALS, vol. 27, 1999, pages 195 - 201 * |
| SCHEFFLER, S. ET AL.: "No influence of collagenous proteins of Achilles tendon, skin and cartilage on the virus-inactivating efficacy of peracetic acideethanol", BIOLOGICALS, vol. 35, 2007, pages 355 - 359 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017019009A1 (en) | 2015-07-27 | 2017-02-02 | Kimberly-Clark Worldwide, Inc. | Residual disinfectant composition |
| EP3337324A4 (en) * | 2015-07-27 | 2019-01-23 | Kimberly-Clark Worldwide, Inc. | Residual disinfectant composition |
| EP3725153A1 (en) * | 2015-07-27 | 2020-10-21 | Kimberly-Clark Worldwide, Inc. | Residual disinfectant composition |
| US10874100B2 (en) | 2015-07-27 | 2020-12-29 | Kimberly-Clark Worldwide, Inc. | Residual disinfectant composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6125660B2 (en) | 2017-05-10 |
| JPWO2015072125A1 (en) | 2017-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017302034C1 (en) | Polymer-based antimicrobial compositions and methods of use thereof | |
| JP7023949B2 (en) | Biocidal composition for use in the laundry washing process | |
| WO2016104967A1 (en) | Cleansing or disinfecting composition having anti-viral activity by comprising green tea extract as active ingredient | |
| CN109169653A (en) | A kind of cation composite disinfectant and its application | |
| US8785621B2 (en) | Method for disinfecting surfaces | |
| JP2013506650A (en) | Sanitizing composition | |
| WO2011123623A2 (en) | Skin, nail and hair topical antimicrobial methods using formulations containing organosilane quaternaries | |
| JP6129843B2 (en) | Disinfecting compositions and their use | |
| JP2008189645A (en) | Composition effective for inactivation of hydrophilic virus | |
| BR112020014234A2 (en) | COMPOSITIONS, KITS, METHODS AND USES FOR CLEANING, DISINFECTION, STERILIZATION AND / OR TREATMENT | |
| JP2004099588A (en) | Synergistic preparation based on mixed liquid of aromatic alcohol and glycerol ether for controlling mycobacteria | |
| CN114554851A (en) | Antimicrobial compositions | |
| US20120288488A1 (en) | Compositions and Methods of Use for Livestock Pen Spray | |
| JP5189291B2 (en) | Viricidal activity of cetylpyridinium chloride. | |
| US20050100612A1 (en) | Virucidal activities of cetylpyridinium chloride | |
| EA025666B1 (en) | Powder composition for disinfection of the teats of dairy animals | |
| JP6125660B2 (en) | Anti-parvovirus composition | |
| JP2009149575A (en) | Antimicrobial agent | |
| WO2014115860A1 (en) | Virucidal agent | |
| JPH072615A (en) | Cloth impregnated with antimicrobial disinfectant | |
| KR20200009520A (en) | Process for Compositions of Disinfectants for High Pathogenic Avian Influenza Virus Including nano- and ionic-Minerals | |
| CN108041098A (en) | A kind of henhouse antibiosis and sterilization agent | |
| US9138004B2 (en) | Chloramine T based teat cleaner and related process | |
| AU2003248583B2 (en) | Food-grade sanitizing composition | |
| JP2022016360A (en) | Antibacterial/antiviral composition and antibacterial/antiviral fiber product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14863021 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2015547630 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 14863021 Country of ref document: EP Kind code of ref document: A1 |